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Abstract
Schlafen 11 (Slfn11) is a ubiquitously expressed interferon stimulating gene (ISG) that
controls synthesis of proteins by regulating tRNA abundance. Through this mechanism Slfn11 has
previously been shown to impair human immunodeficiency virus 1 (HIV-1) infection and the
expression of codon-biased open reading frames. Because replication of positive-sense singlestranded RNA [(+)ssRNA viruses] requires the immediate translation of the incoming viral
genome whereas negative sense, single stranded [(-)ssRNA] viruses carry at infection an RNA
replicase that makes multiple translation competent copies of the incoming viral genome, we
reasoned that (+)ssRNA viruses will be more sensitive to the effect of Slfn11 on protein synthesis
than (-)ssRNA viruses. To evaluate this hypothesis, we tested the effects of Slfn11 on the
replication of a panel of ssRNA viruses in the human glioblastoma cell line A172, which naturally
expresses Slfn11. Depletion of Slfn11 in this cell line significantly increased the replication of
(+)ssRNA viruses from the Flavivirus family, including West Nile (WNV), dengue (DENV), and
Zika virus (ZIKV) but had no significant effect on the replication of the (-)ssRNA viruses vesicular
stomatitis (VSV, Rhabdoviridae family) and Rift Valley fever (RVFV, Phenuiviridae family).
Mutagenesis analysis indicated that the N-terminus of Slfn11 was necessary and sufficient to
restrict WNV replication. To test the mechanism of action of Slfn11, we evaluated the effect of
WNV infection on the tRNA repertoire of cells expressing or not this protein using tRNA PCR
array. WNV infection down-regulated a subset of host tRNAs and this modification was opposed
by Slfn11. Viral protein expression analysis suggests that the changes induced by WNV on the
tRNA pool led to a decrease in viral protein translation efficiency which was accompanied by
production of higher viral titers. In light of these data, we propose that WNV-induced tRNA
changes enhanced co-translational protein folding. Intriguingly, overexpression of Slfn11 in HEK
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293T, HeLa, and BHK-21 cells, all of which naturally lack the expression of this protein, did not
impair infection by WNV or HIV-1, suggesting that other cellular protein(s) absent in these cells
may be required for the antiviral activity of Slfn11. In summary, we have identified Slfn11 as an
important restriction factor on the replication of flaviviruses.
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Chapter 1: Introduction
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1.1

Overarching Hypothesis
Our laboratory is interested in discovering broad spectrum immune mechanisms that target

viral families. These mechanisms are based on the recognition of molecular patterns or processes
shared among evolutionarily distant viral families. We hypothesized that some viruses will be
more sensitive to the efficiency of protein translation than the host. Therefore, mechanisms
regulating protein translation efficiency will contribute to the regulation of viral replication. We
consider that viruses that use a codon biased genome (i.e. lentiviruses) and the positive-sense
single-stranded RNA [(+)ssRNA] viruses will exhibit a greater dependence on protein translation
than the host. tRNA abundance is dictated by host codon usage, therefore, upon infection viruses
with a codon biased genome will encounter a deficiency in tRNAs required for viral protein
expression. In the case of (+)ssRNA viruses, the particular requirement for efficient protein
translation could be determined by their strategy of replication. These viruses multiply their
genome using a virally-encoded RNA-dependent-RNA polymerase that is synthesized using the
incoming viral genome as mRNA. Production of this RNA polymerase triggers massive viral RNA
replication providing multiple translation competent copies of the viral genome, overcoming the
initial bottleneck. Therefore, the requirement of (+)ssRNA viruses to translate the incoming viral
genome suggests that replication of these viruses will be particularly sensitive to the efficiency of
protein translation. In support of this view, during my dissertation work it was reported that
multiple ISGs controlling translation efficiency affect the replication of (+)ssRNA more than ()ssRNA viruses, which do not require immediate translation of the incoming viral genome 1.
Flaviviruses were used as a model of (+)ssRNA viruses in order to test this overarching hypothesis
of our work, with a special focus on WNV. Because of the previously established effect of Slfn11
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on HIV-1 protein translation, this cellular protein was also used as a model for all of the work
described below.

1.2

General Characteristics of West Nile Virus
WNV is an emerging neurotropic flavivirus transmitted primarily by the Culex mosquito

genus. Originally identified in 1937 in the West Nile district of Uganda, it is classified as an
arthropod-borne virus (arbovirus) belonging to the Japanese encephalitis serocomplex of the
Flaviviridae family2. Birds are the main reservoirs for WNV3. The primary vector for WNV in the
United States is the Culex mosquito species that commonly breeds in urban areas and prefers to
feed on birds4. However at least 43 mosquito species in the U.S., including Aedes, Anopheles, and
Psorophora mosquito species, have tested positive for WNV5. The mosquito is responsible for
spreading the virus to humans and horses. However, since viral titers in these hosts are not
sufficiently high enough for a mosquito to obtain virus in a blood meal, they are considered
incidental, dead-end hosts as they do not contribute to the transmission cycle of the virus.
Transmission of WNV has also been reported after blood transfusions and organ transplantation6.
Because of this, in 2003 blood banks began to screen for the presence of WNV in donors’ blood,
which also allowed for better analysis of WNV activity in communities2.
WNV clinical manifestations can range from an asymptomatic infection (70% to 80% of
all infections) to a very broad spectrum of clinical illnesses such as fever, encephalitis, meningitis,
meningoencephalitis, acute flaccid paralysis, an enlarged liver, splenomegaly, mild non-exudative
pharyngitis and myocarditis7. The incubation period for the virus can range from 2-14 days8. IgM
antibody detection to WNV in serum or cerebrospinal fluid is the most common diagnostic
method4. The symptoms of the more severe form of the disease (encephalitis) are: headache, high
fever, vomiting, photophobia, stiff neck, drowsiness, disorientation and muscle weakness
3

progressing to convulsions, coma and paralysis. Neuroinvasive manifestations can last several
weeks and the neurological consequences may be permanent. Old age is the greatest risk factor for
severe neurologic disease, disease complications or even death. The most effective form of
prevention relies on comprehensive mosquito-control programs and methods to avoid mosquito
bites, including the use of mosquito repellents7.

1.3

WNV Virion Structure
WNV belongs to the genus Flavivirus in the Flaviviridae family of viruses, which consists

of more than 70 members including DENV, Japanese encephalitis virus (JEV), yellow fever virus
(YFV) and ZIKV. Although Flaviviruses share similar genome organization and replication
mechanisms, they are able to cause a wide range of severe disease manifestations in humans
including neurological disease such as meningitis or encephalitis (e.g. WNV and JEV) or vascular
leak and haemorrhage (e.g. DENV and YFV)9,10.
WNV virions are small, spherical, enveloped particles of approximately 50 nm in size11.
The viral envelope is a host-derived membrane in which the viral membrane (M) and envelope (E)
proteins are anchored. These proteins have C-terminal regions that are hydrophobic and span the
membrane twice12. The viral capsid is approximately 30 nm in diameter and consists of C protein
dimers, with the RNA binding domains located at the C- and N- termini separated by a
hydrophobic region11. During virion maturation, the N-terminal region of the precursor M (prM)
protein is cleaved by a furin-like protease inside the trans-Golgi network of the infected cell. This
cleavage results in a conformational change in the associated E protein trimers that leads to the
formation of E dimers that interact to form the icosahedral protein shell on the outer side of the
virion envelope13. (Figure 1.1)
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Figure 1.1 WNV virion structure.

1.4

Genome Organization
The virus contains a single-stranded, positive-sense RNA genome of ~11kb in length. The

genome serves as a messenger RNA (mRNA) and also as a template for the synthesis of
complementary minus-strand RNA. The non-coding region (NCR) at the 5’ end of the WNV
genome is ~96nts in length and contains a Type 1 cap, while the length of the 3' NCR varies from
337 to 649nts and does not contain a poly A tail14. The genomic RNA encodes a polyprotein that
is co- and post-translationally processed by viral and host proteases to produce three structural
proteins (E, M and C), and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B
and NS5)13. (Figure 1.2)
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Figure 1.2 WNV genome organization.

1.5

Viral Structural Proteins
The three structural proteins, E, prM/M, and C, are encoded within the 5’ end of the viral

open reading frame (ORF) of the viral genome15. The precursor C protein contains a C-terminal
hydrophobic domain that spans the ER membrane and targets prM for translocation to the ER prior
to cleavage. Precursor C is cleaved at its C- terminus by the viral protease on the cytoplasmic side
of the ER membrane to generate the mature C protein. The mature C protein folds into a dimer
that is composed of 2 monomers each containing 4 α-helices. Internal hydrophobic regions of C
protein mediate association with the ER membrane while nonspecific interactions between the
charged residues at the N- and C-termini of mature C protein and the viral genomic RNA are
thought to facilitate assembly of the nucleocapsid around the genomic RNA16,13.
The M protein (~8 kDa) is a proteolytic product of its precursor glycoprotein, prM (~26
kDa). The C-terminal region of prM contains two transmembrane domains that anchor prM and
M in the ER membrane, and may aid in the heterodimerization of prM and E. The prM protein
maintains surface E proteins in a raised trimeric confirmation, blocking premature viral fusion with
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the cellular membranes during virion trafficking through acidic compartments of the trans-Golgi
secretory pathway12,17.
The major viral surface protein is the E protein, which mediates viral attachment,
membrane fusion as well as virion assembly18. In mature virions, E protein homodimers are
arranged in a head-to-tail conformation and lie parallel to the lipid bilayer19. The E protein contains
the major antigenic determinants on the surface of flavivirus particles 13.

1.6

Viral Non-Structural Proteins
The NS1 protein (~47 kDa) has been shown to exist as a monomer, homodimer and a

hexamer, and is the only flaviviral nonstructural protein known to be glycosylated 13,20,21. NS1 has
been reported to play a role in viral replication, and the hexameric form is secreted from infected
cells and has been reported to inhibit complement activation during WNV infection 15,22,23. The
eight C-terminal residues of NS1 and the ~140 N-terminal residues of NS2A are required for the
cleavage of NS1 from NS2A by an unknown host protease24.
The NS2A and NS2B proteins are small (23 kDa and 13 kDa, respectively) hydrophobic
proteins. Mutations that prevent cleavage at the NS1/NS2A junction have proven lethal for the
virus without affecting viral RNA replication, suggesting a role for NS2A in virion assembly25,26.
In addition, mutational analysis of WNV and Kunjin NS2A demonstrated that this protein mediates
attenuation of type I interferon (IFN) signaling 26,27. NS2B is a membrane-associated protein that
is required as a cofactor for the activity of the serine protease of NS3 28,29.
The NS3 protein is a large (~70 kDa) protein that is highly conserved among flaviviruses.
The N-terminal region comprises the NS3 protease domain that forms an active complex with
NS2B. NS3 cleaves itself from the viral polyprotein and then cleaves at multiple other sites within
the polyprotein30. RNA-stimulated NTPase and RNA helicase activities have been mapped to C7

terminal regions of the NS3 protein. Additionally, the NS3 mediates de-phosphorylation of the 5'
end of the viral genomic RNA prior to cap addition. Collectively, the data establishes the
requirement of NS3 in viral RNA replication31–33.
NS4A and NS4B are small hydrophobic proteins (16 and 27 kDa, respectively) that localize
to the ER membrane. Neither of these two proteins share sequence homology with any known
enzymes. The C-terminus of NS4A is cleaved by both host signal peptidase and viral serine
protease24. NS4A has been shown to interact with NS1 and co-localizes with replication complexes
within vesicle pockets, supporting a role for NS4A/NS1 in RNA replication 34,35. Overexpression
of DENV NS4A induced membrane rearrangements similar to those observed in infected cells 36,37.
Kunjin virus NS4B can induce membrane proliferation and rearrangement and perinuclear protein
accumulation when overexpressed38. NS4A and NS4B play a role in attenuation of the IFN
antiviral response to WNV infection and NS4B was shown to inhibit STAT phosphorylation and
subsequent signaling39,40. NS2A, NS2B, NS3, NS4A and NS4B form ER membrane-associated
complexes in infected cells13.
NS5 is a large (96 kDa) multifunctional protein that is the most conserved flavivirus
protein. The C-terminal region of the NS5 protein contains the viral RNA-dependent RNA
polymerase (RdRp)41. NS5 also has an N-terminal methyltransferase domain that methylates the
cap structure of flaviviral genomic RNAs42,43. NS5 has been shown to interact with NS3 in vivo as
well as in vitro44. Phosphorylation of NS5 by cellular serine/threonine kinases in vivo has been
previously reported and this phosphorylation may regulate NS3-NS5 interactions44–46. Although
predominantly cytoplasmic, the flavivirus NS5 has also been detected in the nuclei of infected
cells44,47. In addition to RdRp and helicase functions, NS5 plays a role in modulating the antiviral
host response. In cells infected with virulent strains of WNV such as NY99, NS5 was shown to be
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an antagonist of IFN signaling by preventing accumulation of STAT1 phosphorylation.
Interestingly, mutation of Kunjin NS5 at S653F increased the virulence of this typically attenuated
strain by making it capable of inhibiting STAT1 phosphorylation48.

1.7

Replication Cycle
During the early stages of WNV infection, the virus typically infects keratinocytes, and

skin-resident dendritic cells (DCs), which include dermal DCs and Langerhans cells 8. Initial
infection is usually followed by viral amplification within draining lymph nodes, which results in
the initial viremia. In some cases, this initial infection can subsequently spread to visceral organs
such as the kidney, spleen and liver. The virus is also able to cross the blood-brain barrier by
stimulating the secretion of tumor necrosis factor (TNF), which induces endothelial cell
permeability. Another possible mechanism by which the virus is able to enter the central nervous
system (CNS) is through hijacking of immune cells able to traffic into the CNS 8.
The first step of the replication cycle starts with binding of the virion E protein to an
unknown host receptor on the surface of the cell membrane. After viral attachment to the cellular
receptor, it enters the cell via receptor-mediated endocytosis through the clathrin-mediated
pathway49. After internalization, viral particles are delivered to early or intermediate endosomes,
which mature to late endosomes. As the environment of the endosome acidifies, the virion E
proteins undergo a conformational change that leads to fusion of the virion E protein with the
endosomal membrane50. Viral-endosomal membrane fusion ultimately facilitates release of the
viral nucleocapsid as well as the genomic viral RNA into the cytoplasm. The entering viral genome
may remain associated with the capsid dimers and this association is thought to help protect the
incoming viral genome from cellular nucleases and pattern recognition receptors (PRR’s) 51.
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Once the nucleocapsid enters the cytoplasm of the host cell, the viral genome is translated
into a single polyprotein that will then be co- and post-translationally processed by the viral serine
protease complex (NS2B-NS3), as well as by other cellular proteases, into a total of 10 mature
viral proteins13. The viral genome also serves as a template for the synthesis of minus-strand RNA.
Genome RNA synthesis is significantly more efficient than that of the minus-strand RNA, usually
resulting in a 100:1 ratio of positive- to minus- strand RNA in infected cells52. The incoming viral
RNA is then translated to produce the nonstructural proteins required for viral RNA replication. It
is essential that efficient viral protein synthesis is established at early times during infection in
order to counteract the cell’s antiviral responses and to rearrange the cell in preparation for
exponential genome synthesis and virion assembly51.
During the early stages of the viral life cycle, the viral genomes in the cell switch back and
forth between functioning as an mRNA for protein translation and as template for minus strand
RNA synthesis51. Viral RNA replication primarily occurs inside perinuclear regions (replication
complexes) that are located inside vesicles that form invaginations of the rough ER membranes 53.
The recently transcribed genomic viral RNA exits the replication complex through a pore and is
either translated into polyprotein or binds to capsid proteins associated with ER membranes in
areas where E and prM proteins are also located, leading to budding into the ER lumen53. Noninfectious, immature viral particles are transported through the trans-Golgi network where prM is
cleaved into the M protein by the host protease furin to generate mature infectious particles that
are transported to the plasma membrane in vesicles 54,55. Virions are released from the cell by
exocytosis as the virus-containing vesicles fuse with the plasma membrane. Typically, WNV
virions begin to be released from infected cells starting at 8 to 10hrs post-infection and peak
extracellular virus titers are usually observed by 24hrs51.
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1.8

Innate Immune Response to Viral Infection
The innate immune system is composed of a series of pattern recognition receptors (PRR’s)

that upon detection of a pathogen-associated molecular pattern (PAMP) are able to induce a strong
antiviral host response, primarily characterized by the production of Type 1 interferon (IFN). Type
I IFN has been found to have an important role in limiting the pathogenicity on WNV infected
animals. IFN-a and IFN-b are able to reduce the viral burden by restricting cellular tropism and
therefore protecting the animals from lethal WNV infection56. In previous animal studies,
treatment of mice with type I IFN-inducing RNA transcripts protects mice challenged with lethal
doses of WNV56.
There are many PRRs encoded by mammalian cells including the Toll-like receptors
(TLR), retinoic-acid inducible gene-I (RIG-I)-like receptors (RLR), and the nucleotide
oligomerization domain (Nod)-like receptors (NLR). These receptors are an essential component
of the antiviral defense program and each of them have been extensively defined as controllers of
immunity and protection against WNV infection, although studies have shown that RLR receptors
are the main regulators of innate immune responses that control WNV infection57–60.
Detection of viral dsRNA and activation of PRRs such as RIG-I or the melanoma
differentiation-associated gene 5 (MDA-5) trigger conformational changes and subcellular
redistribution of these proteins to mitochondrial-associated membranes. RIG-I and MDA-5 will
then interact with the mitochondrial antiviral signaling (MAVS) adaptor protein, leading to
subsequent phosphorylation and nuclear translocation of interferon regulatory factors (IRFs) that
drive transcription of IFN-α/β and ISGs, all essential to the cell’s defense against viral infection 8,57.
IFN responses serve as an essential first line of host defense against many viruses including
flaviviruses. IFNs are classified as Type I and Type II. Both types have antiviral activity61. The
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two types of IFN are structurally unrelated and their actions are mediated by different and
structurally unrelated cell-surface receptors62. IFN produced in an infected cell is secreted and
binds to receptors on the surface of both infected cells and uninfected cells in an autocrine or
paracrine manner. IFN-α/β binding to the IFN-α/β receptor (IFNAR) causes cross-activation of
Jak1 and Tyk2, which phosphorylate one another along with STAT1 and STAT2. The
phosphorylation of these two STATs results in the formation of IFN- stimulated gene factor 3
(ISGF3), a trimeric complex that includes STAT1, STAT2 and IFN regulatory factor (IRF) 9. The
ISGF3 complex translocates to the nucleus where it binds to IFN-stimulatory response elements
(ISREs) and drive transcription of IFN-b, IFN-α4, pro-inflammatory cytokines, and interferonstimulated genes (ISGs) that aid in cellular defense against viral infection57.

1.9

Cellular Function of the Slfn Family of Proteins
The Slfn protein family consists of 10 known or predicted murine genes clustered on

chromosome 11 and 6 human genes clustered on chromosome 1763,64. The family is categorized
into three groups, based primarily on the size of each member65,66. All Slfn proteins contain a Slfn
box, a domain that is not found in other proteins and whose function is currently unknown65. This
protein motif resides near a conserved N-terminus containing a putative AAA-ATPase domain.
Group I Slfns (short form) range from 37 to 42 kDa in size, while group II ranges from 58 and 68
kDa. Group II and III also consists of a specific SWADL domain, defined by a Ser-Trp-Ala-AspLeu signature sequence. Group III Slfns (longest form) range from 100 to 104kDa in size and are
additionally characterized by a C-terminal extension that is homologous to the superfamily I of
RNA helicases65,67,68, a trait they share with the nucleic acid sensors RIG-I and MDA-569 (Figure
1.7). Beyond that, Slfn proteins share no sequence similarity to other proteins.
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Figure 1.7 Structural model of the Slfn protein family.

Slfn genes were originally identified during screening for growth regulatory genes that are
differentially expressed during lymphocyte development70. Although the biological role of the Slfn
family remains poorly understood, some studies have implicated members of this family of
proteins in specific cellular functions. Studies in mice have implicated Slfn proteins in regulation
of cell growth and T-cell development67. Other proposed biological functions of Slfn genes include
involvement in cell differentiation, inhibition of cell proliferation, inhibition of anchorageindependent growth, myeloid differentiation, sensitization to DNA-damaging agents and more
recently, to inhibition of viral replication69,71–73.
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1.10 Cellular Function of the Cellular Protein Slfn11
Early work showed a strong correlation between endogenous Slfn11 expression and the
response of several human cancer cell lines to Topoisomerase 1 and 2 inhibitors, as well as
alkylating agents and DNA synthesis inhibitors; in other words, cancer cell lines expressing high
levels of Slfn11 were significantly more sensitive to FDA-approved DNA-damaging agents
(DDAs). Furthermore, since Slfn11 sensitized cells to DDAs but not to drugs with other
mechanisms of action, it was suggested that Slfn11 must participate in the cell’s DNA damage
response by enforcing cell cycle arrest and promoting apoptosis 74. Further studies have shown
interactions between Slfn11 and the RNA helicase DHX9. This helicase is involved in multiple
cellular processes such as DNA replication, mRNA translation and RNA-mediated gene silencing;
as well as with a subunit of the replication protein A (RPA) protein complex, also involved in
DNA replication, recombination and DNA repair70. High levels of Slfn11 expression is observed
in monocytes and monocyte-derived dendritic cells (moDCs) as well as in CD4 + T cells75.
Intriguingly, high levels of Slfn11 has also been observed in HIV-positive individuals that are able
to maintain undetectable levels of viral loads in the absence of any treatment, also known as HIV
“elite controllers”76.

1.11 Viral Regulation by Slfn Proteins
The first indication of a Slfn family member involved in viral regulation or host immune
responses came in 1998, when known Slfn amino acid sequences were used to perform a BLASTp
query and strong sequence similarities were observed in the right inverted terminal repeats of
vaccinia, variola and cowpox viruses77. Further study revealed that a camelpox virus strain (176R)
encoded a protein with sequence similarity with that of mouse Slfns (v-Slfn)78. Phylogenetic
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analysis shows that the v-Slfn genes are most closely related to mouse and rat Slfn genes,
suggesting that they originated by horizontal transfer from a rodent to orthopoxvirus (OPV) 68. The
camelpox v-Slfn was shown to be expressed at early and late times post-infection. Furthermore,
expression of the camelpox v-Slfn in a vaccinia virus strain resulted in reduced weight loss, faster
rates of recovery and earlier decay of viral titers in mice infected with the recombinant virus.
Additionally, the N-terminal region of v-Slfn (encoding the AAA-ATPase domain) was found to
be responsible for this phenotype78. Although the reason why a virus would encode a protein that
decreases virulence is puzzling, the authors propose the intriguing possibility that OPVs might do
so to prevent overwhelming the host, thereby impeding viral spreading throughout the host
population. In any case, the link between Slfn genes and the interferon immune response clearly
suggests an important interplay between these genes and the host’s antiviral response.
One of the most distinct consequences of viral infection is the induction of IFNs, cytokines
that have potent antiviral activity, along with the activation of interferon- stimulated genes (ISGs).
Members of the Slfn family of genes are a subset of these ISGs that are also induced directly by
pathogens via the interferon regulatory factor 3 (IRF3) pathway79.
Brucella and Listeria infections have been shown to increase the expression of mouse Slfn
proteins69. Similarly, lipopolysaccharide, poly-IC, or IFN-α/β treatment of murine macrophages
resulted in induction of several mouse Slfn genes69. Increased expression of Slfn5 and Slfn11 was
also found in human foreskin fibroblasts treated with IFN-β, poly-IC, or poly-dAdT69. More
importantly, Slfn11 was found to significantly reduce the replication of human immunodeficiency
virus (HIV-1) and equine infectious anemia virus infection69,71. Slfn11 binds to tRNAs and
counteracts the up-regulation of the tRNA repertoire induced by HIV-1 infection that promotes
translation of the codon-biased viral genome, although the exact mechanism by which this occurs
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remains to be elucidated. Furthermore, the antiviral activity of Slfn11 was mapped to the Nterminal half of Slfn11, which includes the AAA+ superfamily of ring-shaped P-loop NTPases.
This domain has been proposed to mediate energy-dependent remodeling or translocation of
macromolecules80.
It is possible that the antiviral mechanism of Slfn11 involves tRNA nucleolytic activity
recently described in Slfn1373. Slfn13 was recently described as a potent tRNA/rRNA-targeting
RNase able to impair HIV-I infection73. All the residues implicated in the tRNA nucleolytic
activity of Slfn13 are conserved in Slfn11, and these two proteins share an overall homology of
83%. This enzymatic activity is required for Slfn13 to restrict HIV-1 infection. Slfn13 cleaves
tRNAs close to the 3’ end at the acceptor stem and also diminishes the levels of HIV-1 mRNA.
The anti-HIV-1 activity of Slfn13 is specific since this protein did not affect replication of herpes
simplex and only moderately impaired ZIKV replication73.
Murine Slfn14 has recently been shown to impair replication of influenza A and varicella
zoster virus. Although the precise antiviral mechanism remains unknown, it was determined that
Slfn14 affects nuclear trafficking of influenza nucleoproteins. Furthermore, Slfn14 induction was
revealed to be mediated by the TLR-3 and type I IFN pathways and that once induced, it enhances
RIG-I-mediated IFN-β signaling72.
In summary, Slfn11, along with other Slfn proteins, is now described as a potent,
interferon-stimulated gene that responds against viral infections and regulates their replication.
Slfn11 was shown to selectively inhibit the synthesis of viral proteins by exploiting the codonusage bias of the virus. Furthermore, Slfn11 was shown to bind to tRNA and effectively counteract
the changes in the tRNA repertoire triggered by HIV-169.
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1.12 Significance and Hypothesis
The medical and veterinary relevance of lentiviruses and (+)ssRNA viruses is clearly
established, as well as the need for preventive vaccines and effective therapeutics. Therefore, the
discovery of viral mechanisms of replication, and in particular mechanisms of evasion of the innate
immune response will pave the way for developing therapies that will synergize with the innate
immune response to eradicate or control these infections. Key players in these innate immune
mechanisms will also serve as biological markers of disease susceptibility, allowing for easier
identification of individuals at higher risk of disease.
We focused our research on flaviviruses, a family of (+)ssRNA viruses including medically
important members such as WNV, DENV, and ZIKV; as well as viruses causing hemorrhagic
diseases including YFV, Omsk haemorrhagic fever virus (OHFV), and Kyasanur forest disease
virus (KFDV). The mortality rate of the infections caused by these agents varies, the highest being
for haemorrhagic fever viruses. None of these viral infections have a specific treatment, and an
effective vaccine is available only against YFV, despite the medical and military significance of
these viruses.
We chose to investigate the role of Slfn11 in flavivirus replication. Slfn11 is an ISG
induced upon viral infection that regulates tRNA abundance, affecting lentiviral infection. Our
knowledge of Slfn11 is extremely limited. At the beginning of this project, approximately 20
papers related to Slfn11 had been published, with only 2 of them related to viruses, and both of
them reporting effects on lentiviruses. Currently, the role of Slfn11 as an antiviral protein remains
poorly understood and the effect of Slfn11 on other viruses, excusing the current study, is yet to
be determined.
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The previously observed effect of Slfn11 on tRNA availability and consequently on protein
synthesis compelled us to hypothesize that this protein would preferentially restrict the replication
of viruses that require high translation efficiency. Thus, we hypothesized that Slfn11 negatively
regulates flavivirus replication. We predicted that knockdown of Slfn11 would enhance
replication of flaviviruses but would have no effect on the replication of (-)ssRNA viruses that do
not have this extreme requirement for initial protein translation. Consequently, we proposed that
overexpression of Slfn11 would selectively restrict replication of (+)ssRNA relative to (-)ssRNA.
Since Slfn11 opposes HIV-induced changes in the tRNA pool69, we also proposed that WNV
infection would modulate the tRNA repertoire in Slfn11-deficient cells to a greater degree than in
Slfn11-expressing cells.
We tested these predictions and found that flaviviruses, including WNV, DENV, and
ZIKV, replicated significantly more efficiently in Slfn11-deficient than in control cells expressing
this protein. As predicted, this phenotype was not observed when the replication of (-)ssRNA
viruses VSV and RVFV was analyzed, highlighting the specificity of this antiviral activity. Our
data also revealed that WNV infection modulates the tRNA repertoire only in Slfn11-deficient
cells.
Our findings support our view that some viruses are more sensitive than the host to protein
translation efficiency, further indicating that the innate immune system exploits this greater
sensitivity to control infection, and that viruses have evolved strategies to counteract these
mechanisms and to enhance viral protein translation efficiency. Undoubtedly, our results will
encourage research directed at clarifying the exact molecular features of these mechanisms of viral
replication and innate immune surveillance.
.
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Chapter 2: Evaluation of the Antiviral Activity of Slfn11

19

2.1

Introduction
Successful viral replication depends on the ability of the virus to take over the host

translational machinery. The innate immune response exploits this dependency to control viral
replication. Many interferon (IFN)-stimulated genes (ISGs) that regulate protein translation are
well known to restrict virus replication, including Protein Kinase R, the Interferon-induced
proteins with tetratricopeptide repeats family of proteins, zinc-finger antiviral protein and the 2′,5′Oligoadenylate/RNaseL pathway65,77. Another family of ISGs is the Schlafen (Slfn) proteins 65,77,
which were first identified as being important regulators of T cell differentiation and growth69.
Currently, 10 mouse (Slfn1, 1L, 2, 3, 4, 5, 8, 9, 10, and 14) and 6 human (Slfn5, 11, 12, 12L, 13,
and 14) Slfn genes have been identified71,81. Slfn11, the focus of the current study, is ubiquitously
expressed and controls synthesis of proteins encoded by codon-biased open reading frames69,71,81.
Several members of the Schlafen family have been shown to impair virus replication.
Mouse Slfn14 impairs replication of influenza A and varicella zoster virus. The mechanism for
this effect is unknown but Slfn14 affects nuclear trafficking of influenza nucleoproteins and
enhances IFN-β signaling72. Human Slfn11 suppresses HIV-1 and equine infectious anemia virus
infection69,71. Slfn11 binds to tRNAs and counteracts the up-regulation of the tRNA repertoire
induced by HIV-1 infection that promotes translation of the codon-biased viral genome. The antiviral mechanism of Slfn11 seems to involve a tRNA nucleolytic activity recently described in
Slfn1373. All the residues implicated in the tRNA nucleolytic activity of Slfn13 are conserved in
Slfn11, and these two proteins share an overall homology of 83%.
Therefore, we decided to investigate whether the previously observed antiviral activity of
Slfn11 can be extended to an evolutionarily-unrelated family of viruses, as well as attempt to
provide insights into the mechanisms of antiviral activity.
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2.2

Materials and Methods

2.2.1 Cell and Virus Culture
HEK293T, HeLa, SupT1, LLC-MK2, BHK-21, and A172 cells were obtained from the
American Type Culture Collection (Manassas, VA). HEK 293T, HeLa, BHK-21, and A172 cells
were maintained in Dulbecco’s Modified Eagle’s (DMEM) medium, LLC-MK2 and BHK-21 cells
in Eagle’s Minimum Essential Medium (E-MEM), and SupT1 cells in RPMI 1640. These culture
media were supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin, streptomycin,
and 1% non-essential amino acids (NEAA), 1% sodium pyruvate. Maintenance media used to
perform viral infections consisted of E-MEM w/L-glutamine, supplemented with 2% FBS, 1%
NEAA, 1% sodium pyruvate and 1% penicillin and streptomycin.
The WNV strain TVP-7767 (Passage: Vero, #3), RVFV strain MP-12 (Passage: Vero, #3)
and ZIKV strain MR-766 (Passage: suckling mice brain, #150. Vero, #3) were obtained from the
World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical
Branch. DENV-2 strain 16681 (Passage: C6/36, #9) was obtained from the Navy Medical Research
Center-6. VSV engineered to express eGFP has been previously described 82. Viral stocks were
prepared in Vero cells maintained in E-MEM supplemented with 2% FBS. Infectivity titers of each
virus stock was determined via plaque assay as described below.
A replication-defective HIV-1 reporter virus (Hluc) was used that expressed LTR-driven
luciferase from the NEF slot and contains a large deletion in ENV 83. Hluc was generated by
calcium phosphate transfection of the corresponding HIV-1 expression plasmid (pHluc, 15 ug) and
the VSV-G encoding plasmid pMD.G (5 ug) into HEK293T cells, as described before 83. In
accordance with World Health Organization’s and the Centers for Disease Control and
Prevention’s guidelines, all work involving infectious WNV was performed in a biosafety level
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(BSL)-3 laboratory in accordance to biosafety practices described in the 2018 revised version of
the University of Texas at El Paso’s (UTEP) BSL 3 Biological Safety Manual and Standard
Operating Procedures. All work involving DENV, VSV, ZIKV, HIV-1, and RVFV MP-12 was
performed in BSL-2+ laboratory in accordance to biosafety practices described in the UTEP
Biological Safety Manual.

2.2.2 Virus Replication Dynamics
All cell lines infected with WNV, DENV, RVFV, ZIKV and VSV were seeded in T25 cell
culture flasks (2.5x105 cells in 2ml total volume) and allowed to grow overnight. The following
day the cells were infected with respective viruses and incubated at 37°C for 1 hr. Cells were
subsequently washed three times with serum-free medium to remove input virus, replenished with
maintenance medium and incubated at 37°C. Cell culture supernatants were collected every 8hrs
until experiments were stopped and stored at -80°C.

2.2.3 Plaque Assays
WNV and VSV viral titers were determined as previously described 84. Briefly, viral
supernatants were subjected to ten-fold serial dilutions and inoculated onto confluent monolayers
of LLC-MK2 cells in 12-well cell culture plates and incubated at 37°C for 1 h with gentle rocking
every 15 minutes. The cells were then overlaid with 1 ml of 0.5% agarose in E-MEM maintenance
medium. Cells were incubated at 37°C for 3 days and then stained with 1g/L of Napthol Blue
Black, 13.6g/L of Sodium Acetate Anhydrous, 60ml/L glacial acetic acid to visualize plaques.
Plaque formation on each cell line was quantified and viral titers were expressed as plaque-forming
units per milliliter (PFU/ml).
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DENV titers were determined as previously described 85. Briefly, 3 x 105 BHK-21 cells
were seeded in 12-well cell culture plates, and then infected with viral supernatants at 37°C for 3
hrs, followed by the addition of 1ml of 3% carboxymethylcellulose overlay medium. Cells were
cultured for 5 days, followed by staining and quantification as described above.
RVFV and ZIKV plaque assays were performed as described for WNV but using Vero 76
cells. RVFV- and ZIKV-infected cells were cultured at 37°C for 4 or 5 days, respectively. Staining
and quantification was performed as described above.
Plaque assays for estimating viral titers were conducted in triplicate experiments with
samples derived from independent viral infections.

2.2.4 Immunoblotting
Full procedures for protein detection by immunoblot have been described previously86.
Briefly, cellular lysates were obtained by lysing cells with 2x Laemmli Buffer and boiling for 10
minutes. Cell lysates were resolved by SDS-PAGE and transferred overnight to PDVF membranes
at 100 mA at 4°C. Membranes were blocked in TBS containing 10% milk for one hour and then
incubated in the corresponding primary antibody diluted in TBS-5% milk-0.05% Tween 20
(antibody dilution buffer). Full-length Slfn11 and Slfn11 C-terminus mutant were detected with
anti-Slfn11 antibody E-4 (Santa Cruz Biotechnology 1/500). The Slfn11 N-terminus mutant was
detected with anti-Slfn11 antibody D-2 (Santa Cruz Biotechnology 1/500). WNV envelope protein
was detected with antibody PA1-41073 (Thermo Fisher Scientific, 1/500). Tetherin (BST-2) was
detected with anti-BST-2 antibody (Santa Cruz Biotechnology 1/500). α-tubulin was detected as a
loading control with antibody from clone B-5- 1-2 (Sigma, 1/4000). Membranes were incubated
overnight at 4°C with primary antibodies, whereas anti-α-tubulin Mab was incubated for 30
minutes at 25°C. Primary antibody-bound membranes were washed in TBS-0.1% Tween 20 and
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bound antibodies detected with goat anti-mouse IgG-HRP (1/2000, Sigma) or a goat anti-rabbit
IgG-HRP (1:4000, EMD Millipore) followed by chemiluminescence detection. Densitometry
analysis of selected bands was quantified based on their relative intensities using Image Studio
Software (LI-COR, Lincoln, NE).

2.2.5 Plasmids
For the generation of HIV-1-derived viral vectors, plasmids were obtained from Eric
Poeschla laboratory (Mayo Clinic, Rochester, MN)87. These lentiviral vectors were used to express
Slfn11- and control-shRNAs and Slfn11 proteins. They were generated with packaging plasmid
pCMVΔR8.91, a transfer plasmid derived from pTRIP (described below), and the envelope
plasmid pMD.G encoding the vesicular stomatitis virus glycoprotein G (VSV-G).
Slfn11- and SCR-shRNA plasmids: An shRNA construct (Top: 5’-GATCCGGCTCAGA
ATTTCCGTACTGAATTCAAGAGATTCAGTACGGAAATTCTGAGCTTTTTTGGAAA-3’,
Bottom:5’-AGCTTTTCCAAAAAAGCTCAGAATTTCCGTACTGAATCTCTTGAATTCAGT
ACGGAAATTCTGAGCCG-3’) against Slfn11 was designed using a target sequence that has
been previously described69. Briefly, Slfn11 shRNA construct was ligated into the pSilencer 2.1
U6 Hygro shuttle vector (AM5760, Thermo Fisher Scientific) and sequence verified. Control
shRNA contains a scrambled sequence (SCR) that was obtained from the negative control plasmid
provided with the kit. The Slfn11 and SCR shRNA expression cassettes were amplified by PCR
and ligated into a unique PpUMI site in the HIV-1-derived transfer plasmid pTRIP-eGFP and their
sequences verified.
shRNA-resistant Slfn11 expression plasmid: The shRNA-resistant Slfn11 cDNA was
engineered by introducing 7 synonymous mutations within the 21nt-long shRNA target sequence
of Slfn11. Plasmid pCDNA-V5-His-Slfn11 (Michael David, University of California San Diego) 69
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was used as template for the Phusion High-Fidelity DNA polymerase (ThermoFisher, F530S).
Primers used to introduce mutations were forward: 5’-TCGGACCGAGGATGGGGACTGGTAT
GGG-3’ and reverse: 5’-AAGTTTTGCGCTTCGTCAATGACG-3’. The newly created shRNA
escape mutant cDNA was then amplified using the high-fidelity Deep Vent DNA polymerase
(New England Biolabs), digested with SbfI and SpeI restriction enzymes, cloned into unique SbfISpeI sites in the pTRIP-IRES-P HIV-1-derived transfer plasmid, and the sequence verified.
N- and C-terminal Slfn11 mutant expression plasmids: pTRIP-IRES-P-Slfn11-shRNAresistant plasmid was used as template to generate the Slfn11 truncated mutants using the
QuikChange Lightning site-directed mutagenesis kit (Agilent Technologies). The mutant
expressing N-terminal Slfn11 (amino acids 1-441) was generated with primers forward: 5’-GAA
CAAAAACTCATCTCAGAAGAGGATCTG-3’, and reverse: 5’-GAAGATCAAAATTCCCCG
AAAGAAAG-3’ whereas forward: 5’-TCTAGAAGTTGGGCTGTGGACC-3’ and reverse: 5’-C
ATACTAGTGGATCCTCTAGC-3’ were used to produce C-terminal Slfn11 (amino acids 442901). Mutants were verified by DNA sequencing.

2.2.6 Production of Lentiviral Vectors
The full procedures for transfection and production of lentiviral vectors has been described
previously83,87,88. Briefly, HEK293T cells were calcium-phosphate transfected with the
corresponding transfer plasmid derived from pTRIP (15 ug), the packaging plasmid pCMVΔR8.91
(15 ug), and VSV-G envelope expression plasmid pMD.G (5 ug). The viral supernatants were
harvested 48 hrs post-transfection and concentrated by ultracentrifugation at 124,750g for 2 hrs on
a 20% sucrose cushion.
Expression of Slfn11- and SCR-shRNA in A172 cells. A172 cells were transduced with
shRNA-, eGFP-expressing lentiviral vectors and cells expressing the highest 10% of eGFP
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fluorescence were isolated by cell sorting and expanded in culture. Slfn11 levels were determined
in these cells by immunoblot, as described above.
Expression of Slfn11 full-length and deletion mutants in Slfn11-dificent cell lines: A172KD, HEK293T, BHK-21, and HeLa cells were engineered to express Slfn11 proteins by
transduction with lentiviral vectors expressing Slfn11 and the puromycin resistant gene. Briefly,
viral vectors were produced in HEK293T by transfection with the transfer plasmid pTRIP-IRESP-Slfn11-shRNA-resistant plasmid expressing Slfn11 full-length or deletion mutants (15 ug) and
the packaging and envelope expression plasmids described above. Viral supernatant was
concentrated by ultracentrifugation and used to transduce cells. Three days later, transduced cells
were selected in the presence of puromycin (A172-KD and HEK293T: 3ug/ml, HeLa: .375ug/ml,
BHK-21: 6ug/ml). Slfn11 expression was verified by immunoblot.

2.2.7 Single-Round Infectivity Assay
HEK293T-, HeLa- and A172-derived cells were seeded onto 24-well plates (2x104
cells/well) and allowed to grow overnight. The next day, cells were infected with Hluc and 24 hrs
later the cells were extensively washed to remove the input virus. Four days later cell culture
supernatant was collected for HIV-1 p24 quantification and cell lysates prepared in a buffer
containing 1% Triton X-100 for luciferase activity quantification (Bright-Glow Luciferase Assay
System, Promega), following the manufacturer’s instructions. Luciferase activity was determined
in triplicate samples using a microplate luminometer reader (Thermo Scientific, Luminoskan
Ascent). Luciferase and HIV-1 p24 samples were derived from at least three independent
infections.
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2.2.8 HIV-1 p24, IFN-α and IFN-β ELISAs
HIV-1 infection was measured by quantifying HIV-1 p24 in the supernatant of infected
cells (described above) by ELISA (ZeptoMetrix Corporation, 0801008). IFN-α and β was
quantified in the cell supernatant of the infected cells by ELISA (PBL Assay Science, Cat # 411151 for IFN-α and # 41415-1 for IFN-β). ELISAs were performed according to the manufacturer’s
instructions.

2.2.9 Indirect Immunofluorescence Microscopy
This technique was used for determining WNV infection in A172-derived cells and for
localizing Slfn11 in A172- and HEK293T-derived cells. A172-derived cells (1.5x104/well) were
seeded onto 96-well confocal microscopy plates and infected with WNV at MOI 1 twenty-four
hours later. Infected cells were fixed and permeabilized with Cytofix/Cytoperm buffer (BD
Biosciences, Cat# 554714) at 24hrs and 48hrs post-infection and then stained with an antiFlavivirus group antigen monoclonal antibody that recognizes WNV Env (ATCC, clone D1-4G24-15, 1/200) for 2hrs at room temperature. Cells were then washed 3 times with PBS containing
0.1% FBS and then incubated with Alexa 568-conjugated antibody (Invitrogen, H-11004,
10ug/ml) for 1h at room temperature. Cells were again washed 3 times with PBS and cell nuclei
was stained with Hoechst 33342 (Invitrogen, H-3570, 20ug/ml) for 10 min.
For subcellular localization of Slfn11, uninfected A172- and HEK293T-derived cells were
staining as described above. Specifically, Slfn11 full-length and C-terminus were detected with
the anti-Slfn11 antibody E-4 (Santa Cruz Biotechnology, sc-374339, 1/200) and the Slfn11 Nterminus mutant was detected with anti-Slfn11 antibody D-2 (Santa Cruz Biotechnology sc515071,1/200).
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2.2.10tRNA PCR-Array and Analysis
To determine the effects of WNV infection on the host tRNA repertoire, we quantified the
tRNA pool using a PCR-based methodology previously described89. The procedure and data
analysis were performed by Arraystar Inc. using the nrStarTM Human tRNA Repertoire PCR Array.
A172-derived cells were infected with WNV at MOI 1 for 1hr at 37°C washed with fresh culture
media and replenished with culture media. 8 hrs post-infection, cells were collected, and total
cellular RNA was extracted using Trizol reagent. Experiments were performed in triplicate with
appropriate non-infected controls. Total cellular RNA was sent to Arraystar Inc for analysis.
Briefly, quality control was performed on extracted RNA samples by NanoDrop ND-1000 and
RNA integrity and genomic DNA contamination were assessed by denaturing agarose gel
electrophoresis. Next, RNA samples were subjected to a demethylation step, followed by firststrand cDNA synthesis (Arraystar, rtStarTM tRNA-optimized First-Strand cDNA Synthesis Kit,
Cat# AS-FS-004). Real-time PCR was then performed using a proprietary human tRNA Repertoire
PCR Array that is able to distinguish 66 nuclear tRNA isodecoders, covering all anti-codons
available in GtRNAdb and tRNAdb databases. Three stably expressed small ncRNA genes RNU62 (Ref 1), SNORD43 (Ref 2), and SNORD95 (Ref 3) were included in the array as the
quantification references for tRNA and data normalization. One external RNA Spike-In mix was
added in the RNA sample prior to the first strand cDNA synthesis. The RNA Spike-In control
assay indicated the overall success and the efficiency of the reaction beginning from the cDNA
synthesis to the final qPCR. For positive PCR control, two replicates of one artificial DNA and the
PCR primer pairs were used to indicate the qPCR amplification efficiency. Only Ct value greater
than 35 were considered as good qPCR amplification efficiency and considered for analysis. The
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positive PCR control was used as an inter-plate calibrator and a control to exclude genomic DNA
contamination.

2.2.11Bioinformatics Analysis
Analysis of the impact of WNV-induced changes in tRNA on viral protein translation was
performed by using a python script created to determine the differential tRNA expression values
over the open reading frames within the viral genome. In short, the tRNA differential expression
values were uploaded from text file into a python dictionary. For each codon not found within the
tRNA expression dataset the codon value was set to 0, and for redundant codons were limited to
the value of the highest expression to limit the codon to a single value. Additionally, to make
visualization of the values easier, a sliding window approach was taken to average the differential
expression over a desired number of amino acids. The window was then shifted by a consistent
step size, and the average again determined. To allow for variation in the resolution of the graphs,
the window size and step size were coded as adjustable parameters within the python script for
easy adjustment. For each gene, the individual codon usage and the windowed average values were
written to a CSV file. The CSV file was then imported into Excel and graphs were then created
from the windowed codon usage.

2.2.12Statistical Analysis
All data used for viral replication curves were transformed to log 10pfu/ml. Repeatedmeasures ANOVA was used to test the impact of different cell lines expressing or not Slfn11 on
viral replication curves and the Tukey-Kramer post-hoc test was used to identify significant
differences in viral titer between cell lines.
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2.3

Results

2.3.1 WNV Infection Induces Expression of Slfn11
To determine whether WNV infection modulates levels of Slfn11 expression, cells of the
human glioblastoma cell line A172 were infected with WNV at MOI: 0.1 and viral replication and
expression of Slfn11 was determined at different times post-infection (p.i.) by plaque assay and
immunoblot. Viral replication was detectable as early as 8 hrs pi and peaked by 32 hrs after
infection (Fig. 2.1a). Corresponding with the peak of viral replication, we detected a sustained
increase in the basal levels of Slfn11 after 40 hrs pi (Fig. 2.1b). Densitometry analysis of
immunoblots from two independent infection experiments indicated that WNV infection caused
3.5-fold increase in the α-tubulin-normalized Slfn11 protein levels after 40 hrs p.i. Therefore, these
data indicated that Slfn11 is up-regulated by WNV infection.
The up-regulation of Slfn11 in WNV-infected cells could be secondary to the production
of type I IFN in response to the viral infection. Therefore, we evaluated the temporal sequence in
production of these proteins. A172 cells were infected with WNV as described above and levels
of IFN-α and -β were determined in the cell supernatant by ELISA. IFN-α and -β were
undetectable, <1.95 pg/ml and <2.3pg/ml, respectively, at 8 hrs p.i even though viral replication
was evident by this time (Fig. 2.1c). However, type I IFNs production was evident by 32 hrs,
reaching a peak at 48 hrs post-infection. Therefore, these data indicated a temporal correspondence
between type I IFN secretion and the up-regulation of Slfn11 suggesting that virus-induced type I
IFN up-regulated Slfn11 expression.
To further evaluate the role of type I IFN in the regulation of Slfn11 expression a panel of
cell lines susceptible to WNV infection was treated with IFN α-1 for 24 hrs and then the levels of
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Slfn11 was determined by immunoblot. Similar to WNV infection, IFN α-1 triggered a two-fold
increase of Slfn11 in A172 cells (Fig. 2.1d). However, this treatment failed to induce expression
of Slfn11 in HEK293T or HeLa cells, which also lack basal expression of this protein. To verify
that IFN α-1 stimulated these cells, we also measured the expression of the ISG tetherin. As
previously reported90, tetherin was constitutively expressed in HeLa cells but not in HEK293T
cells and the expression of this protein increased in both cell types in response to IFN α-1
stimulation (Fig. 2.1d). Tetherin was absent in untreated A172 cells but was also significantly
induced after IFN α-1 treatment. Therefore, the lack of response to IFN α-1 was not the reason for
the absence of Slfn11 in HeLa and HEK293T cells.
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Figure 2.1 Kinetics of WNV replication, type I interferon production, and Slfn11 expression in
A172 cells.
(a) WNV replication in A172 cells. Cells were infected with WNV at MOI 0.1 and viral replication
was measured by titration of the cell supernatant in a plaque assay at different times post-infection.
Titers were determined in triplicate experiments. Data are representative of 3 independent infection
experiments. (b) Expression of Slfn11 in WNV-infected A172 cells. Cells were lysed at different
times post-infection and Slfn11 and α-tubulin (loading control) were detected with specific
antibodies by immunoblot. Data are representative of 2 independent infection experiments. (c)
Kinetics of IFN-α and IFN-β (all subtypes) production in WNV-infected A172 cells. Culture
supernatant was collected at different times post-infection and type I IFN quantified by ELISA.
Data are representative of 3 independent infection experiments. (d). Effect of IFN-α1 on Slfn11
expression. HeLa, A172, and HEK293T cells were treated with 5000U/ml units of IFN-α1 for 24
hrs and the expression of the type I IFN-stimulated genes Slfn11 and Tetherin were evaluated by
immunoblot.
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2.3.2 Slfn11 Impairs Replication of Flaviviruses but not of (-)ssRNA Viruses
To test the relative effect of Slfn 11 expression on (+)ssRNA and (-)ssRNA viruses, A172
cells were stably transduced with lentiviral vectors expressing shRNAs containing Slfn11-specific
or scrambled sequences to generate Slfn11-deficient A172 cells (A172-KD) and control cells
(A172-SCR), respectively. Subsequently, A172-KD cells were engineered to over-express Slfn11
(A172-BC). Levels of Slfn11 were verified in these cells by immunoblotting (Fig. 2.2a). Then,
A172-derived cell lines were infected with WNV at a MOI of 0.1 and cell culture supernatants
were collected every 8 hrs to measure viral titer by plaque assay.
For all the replication curves reported in this study, we analyzed the data with repeated
measures ANOVA, and we always detected a significant effect of time p.i. on virus titer; as this
effect was expected and is not of interest we do not report it here. Instead we focus on whether
there was a significant interaction between treatment (i.e. cell type) and time, or, in the absence of
such interaction, an independent effect of treatment, and we use Tukey-Kramer post-hoc tests to
elucidate the nature of these effects.
As shown in Figure 2.2b, there was a significant interaction of the effects of cell type (KD,
SCR or BC) and time p.i. on WNV titer (DF =14, F = 11.1, P< 0.0001). Overall, WNV replicated
significantly more efficiently in A172 cells lacking Slfn11 than in either of the two cell lines
expressing this protein (Fig 2.2b). Twenty-four hrs post- infection viral titers were 2 logs higher
in Slfn11-deficient cells than in control cells and these differences persisted until 96 hrs postinfection, after which the experiments were terminated due to significant cytopathic effects.
We anticipated Slfn11 to impair WNV replication by targeting viral protein production.
Therefore, we infected A172-derived cells with WNV at a MOI of 0.1 and measured cellassociated WNV Env at the peak of infection (40 hrs p.i.) by immunobloting analysis. As expected,
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Slfn11-deficient cells expressed higher levels of WNV Env than control cells (Fig. 2.2c).
Densitometry analysis of the immunoblots corresponding to three independent infection
experiments indicated that α-tubulin-normalized Env levels were similar between A172-SCR and
-BC cells and A172-KD cells expressed 12.3-fold more Env protein than A172-SCR cells. These
results were expected based on the WNV titer reached in these cells and in the postulated
mechanism of action of Slfn11.
In addition, we verified WNV Env expression by indirect immunofluorescence. A172derived cell lines were infected with WNV at MOI of 1 and the production of WNV Env was
evaluated 24 and 48 hrs after infection by indirect immunofluorescence with an anti-flavivirus
antibody that reacts with WNV Env. In correspondence with data in figure 2.2c, Slfn11-deficient
cells expressed higher levels of Env than A172-SCR and -BC cells at 48 hrs pi (Fig. 2.2d). As
expected, analysis at 24 hrs post-infection showed similar results (data not shown). Subcellular
distribution of Env was similar in all the cell lines, indicating the absence of gross defects in Env
intracellular trafficking. Therefore, data in figures 2.2b-d demonstrated that Slfn11 markedly
impaired the replication of WNV by impairing viral protein expression.
We next tested whether Slfn11 affected replication of two additional flaviviruses, DENV
and ZIKV. Contrary to WNV, DENV does not replicate efficiently in A172 cells; however, we
were interested in determining the contribution of Slfn11 to this phenotype. A172-derived cells
were infected with DENV at MOI 0.1 and viral replication was followed at different times postinfection by titration of the cell supernatant by plaque assay. Data in figure 2.3a showed
statistically significant interactions (DF=8, F=24.4, P<0.0001). Interestingly, although A172-SCR
cells did not support replication of DENV (Fig. 2.3a), Slfn11-deficient A172 cells efficiently
allowed DENV replication, producing 2-log higher viral titters than A172-SCR cells at the peak
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of replication. DENV reached titers of 106 pfu/ml in A172-KD cells with a replication kinetic
similar to that of WNV. In these experiments, DENV replication peaked from 24 to 32 hrs postinfection and then decayed by 48 hrs due to cytopathic effects. As expected, re-expression of
Slfn11 in A172-KD cells (A172-BC cells) fully removed the permissiveness of these cells,
highlighting the specificity of the effect of Slfn11 on DENV replication. Similarly to A172-SCR
cells, DENV did not multiply in A172-BC cells. Therefore, basal expression levels of Slfn11
significantly contribute to the restriction of DENV replication in A172 cells.
Slfn11 and Slfn13 impair HIV-1 infection through a similar mechanism69,73. However,
Slfn13 fails to restrict ZIKV replication73 and the effect of Slfn11 on this flavivirus has not been
explored yet. Thus, we determined whether or not Slfn11 impairs the replication of ZIKV. A172derived cells were infected and ZIKV titer was quantified as described above. ZIKV replication
peaked at 40 hrs post-infection and plateaued until 96 hrs post-infection or the end of the
experiment. However, cytopathic effects were not very apparent even at these late time points of
the infection. Importantly, replication of ZIKV was also significantly enhanced by deficiency of
Slfn11 (Fig. 2.3b), although the intensity of the effect was less marked than for WNV and DENV
(DF=14, F=3.44, P<0.0009). Nevertheless, a significant difference of approximately 7-fold higher
titer was observed in A172-KD versus the control cells from 24 to 48 hrs post-infection. Therefore,
Slfn11 restricts ZIKV replication in contrast to Slfn1373.
For comparison with patterns of (+) and (-)ssRNA virus replication, we also tested the
impact of Slfn11 knockdown and overexpression on the replication of the (-)ssRNA viruses VSV
and MP12-RVFV. Replication of both viruses was very robust in A172 cells showing a kinetic
similar to that of WNV with a peak of viral replication 24 hrs post-infection (Fig. 2.3c-d).
However, the replication of these (-)ssRNA viruses was very similar in terms of kinetics and titers

36

among the different A172-derived cell lines evaluated, despite their differences in Slfn11
expression. Therefore, there was no interaction between the effects of cell line and time p.i. on
virus titer (VSV, DF=12, F=0.21, P=0.9963; RVFV, DF=12, F=0.74, P=0.6974).
The VSV used in these experiments is a recombinant virus expressing eGFP 82. Therefore,
we also evaluated the titer of this virus obtained in the supernatant of the different A172-derived
cell lines by flow cytometry analysis. A172-SCR and -KD cells were infected with three different
MOIs of VSV (0.1, 0.3, and 1) in triplicates and viral supernatant was collected 24 hrs later. Then,
SupT1 cells were infected with the viral supernatants and evaluated 24 hrs after infection by FACS
analysis. In accordance with the plaque assay experiments, we observed a similar titer for the virus
obtained from A172-SCR (8.55 x104 +/- 0.84) and -KD (8.58 x104 +/- 0.91) cells. In summary,
data in Figs 2.3c-d indicated that Slfn11 did not influence the replication of the (-)ssRNA VSV
and RVFV, highlighting the specificity of the antiviral activity of this protein for (+)ssRNA viruses
and lentiviruses69,71.
From the results presented about it is also noteworthy that despite A172-BC cells
expressing markedly higher levels of Slfn11 than A172-SCR cells (Fig. 2.2a), replication of
flaviviruses was similar in these two cell lines (Figs. 2.2b and 2.3a-b), indicating that above certain
levels the antiviral effect of Slfn11 reaches saturation.
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Figure 2.2 Effect of Slfn11 on WNV replication.
(a) Immunoblot analysis of the expression of Slfn11 in A172 cells stably expressing shRNAs
directed against Slfn11 (A172-KD) or a scrambled (A172-SCR) RNA sequences and A172-KD
cells engineered to re-express Slfn11 (A172-BC). α-tubulin was detected as a loading control. (b)
WNV replication in A172-derived cells. A172-SCR (open triangles), A172-KD (filled squares)
and A172-BC (filled diamonds) cells were infected with WNV (MOI 0.1) and viral replication was
determined by quantification of the viral titer in the cell supernatant at different hours postinfection by plaque assay. Statistically significant differences were calculated with repeated
measures ANOVA and Tukey-Kramer post-hoc tests and they are indicated with asterisks. Mean
and standard deviation values represent the variability of the viral titer found in triplicate plaque
assays of samples from 8 independent infection experiments performed in different days with
different viral preparations. (c) Expression of WNV Env in cells infected at MOI 0.1 evaluated by
immunoblot 40 hrs after infection. α-tubulin was detected as a loading control. These results are
representative of 3 independent infections. (d) Expression of WNV Env (red) as detected by
indirect immunofluorescence analysis of cells infected at a MOI of 1 48 hrs post-infection. Nuclei
were labeled with Hoechst (blue).
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Figure 2.3 Effect of Slfn11 on viral replication.
A172-SCR (open triangles), A172-KD (filled squares) and A172-BC (filled diamonds) cells were
infected with (a) Dengue Virus (DENV, MOI 0.1), (b) Zika Virus (ZIKV, MOI 0.1), (c) Vesicular
stomatitis virus (VSV, MOI 0.1), and (d) Rift Valley fever virus (RVFV, MOI 0.1). Viral
replication was determined by quantification of the viral titer in the cell supernatant at different
hours post-infection by plaque assay. Statistically significant differences are indicated with
asterisks and were calculated as described above. Mean and standard deviation values of each
graphic represent the variability of the viral titer found in triplicate plaque assays of samples from
3 independent infection experiments performed in different days with different viral preparations.
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2.3.3 Mutagenesis Analysis of Slfn11 Antiviral Activity
The N-terminal region of Slfn11 and Slfn13 harbors the anti-HIV-1 activity of these
proteins69,73. Not surprisingly, in both proteins this region contains residues that are responsible
for the tRNA nucleolytic activity in Slfn1373, which is central in the anti-HIV-1 activity of these
proteins. Therefore, we followed a previously described strategy69 to determine whether the antiWNV activity of Slfn11 also resides in the N-terminal region.
The N-terminal (amino acids 1-441) and the C-terminal (amino acids 442-901) regions of
Slfn11 were expressed in A172-KD cells to generate A172-N-term and A172-C-term cell lines
(Fig. 2.4a) and their susceptibility to WNV was evaluated (Fig. 2.4b). Cells were infected with
WNV at MOI 0.1 and viral replication was followed by plaque assay, as described above. WNV
replication was impaired in cells expressing N-terminal Slfn11. Viral replication was similar in
these cells and in A172-BC cells that express full-length Slfn11. However, WNV replication was
significantly higher in cells expressing Slfn11 C-terminus (DF=14, F=11.69, P<0.0001, Fig. 2.4b).
Therefore, these findings suggest a common antiviral mechanism of action of Slfn11 against HIV169 and WNV.
In order to define whether the subcellular distribution impacts the antiviral activity of
Slfn11, we determined the localization of Slfn11 full-length and truncation mutants. A172-BC, N-term and -C-term cells were stained with anti-Slfn11 antibodies directed against the N-terminus
or the C-terminus of the protein and Slfn11 cellular distribution was determined by confocal
microscopy analysis. Full-length Slfn11 accumulates in the nucleus, distributing homogenously in
this organelle (Fig. 2.4c). However, both the C- and N-terminal Slfn11 proteins were uniformly
distributed in the cytoplasm of the cell (Fig. 2.4c). The lack of association of antiviral activity and
subcellular distribution of Slfn11 suggests that the process targeted by this protein is accessible in
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both the nucleus and the cytosol. In addition, these data confirm that the inactivity of the C-terminal
region of Slfn11 is not determined by miss localization or a gross defect in intracellular solubility
of this protein, for example due to the formation of protein aggregates.
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Figure 2.4 Mutagenesis analysis of antiviral activity of Slfn11.
(a) Immunoblotting analysis of the expression of Slfn11 in A172-derived cells. A172-KD cells
were engineered to express the N- or C-terminus of Slfn11. A172-SCR, -KD, and BC were used
as control. Different anti-Slfn11 antibodies were employed to identify the mutant proteins. αtubulin was detected as a loading control. (b) A172-BC (filled diamonds), A172-N-term (filled
triangles), and A172-C-term (filled circles) were infected with WNV (MOI 0.1) and viral
replication was determined by quantification of the viral titer in the cell supernatant at different
hours post-infection. Statistically significant differences were calculated as described above and
are indicated with asterisks. Mean and standard deviation values represent the variability of the
viral titer found in triplicate plaque assays of samples from 3 independent infection experiments.
(c) Cellular distribution of Slfn11 full-length and deletion mutants. A172-BC, A172-N-term, and
A172-C-term cells were fixed/permeabilized and stained with the anti-Slfn11 antibodies used in
panel (a). Cell nuclei were identified with Hoechst staining (Blue staining).
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2.3.4 Effect of WNV Infection and Slfn11 Expression on the tRNA Repertoire
of A172 Cells
A previous report indicated that Slfn11 counteracts HIV-1-induced increase of tRNA
abundance, affecting viral protein expression69. Therefore, we explored whether WNV infection
also induces changes in the tRNA repertoire and whether these changes are opposed by Slfn11.
A172-SCR, -KD, and -BC cells were infected with WNV at a MOI of 1 and their tRNA repertoire
was determined 8 hrs later by tRNA PCR array, as previously described 69,89. To ensure data
robustness, the tRNA repertoire of A172-derived cells infected and non-infected was determined
by using RNA obtained from three sets of independent experiments. We chose to evaluate the
tRNA repertoire at 8 hrs post-infection because at this early time point of the life cycle the WNV
was already replicating (Fig. 2.1a and 2.2b) and the infected cells exhibit similar viral loads (Fig.
2.2b), were not producing type I IFN (Fig. 2.1c) nor undergoing cell death (data not shown).
Therefore, modifications in the tRNA pool at 8 hrs post-infection is likely be a direct consequence
of the infection of these cells with similar amount of virus. Furthermore, at 8 hrs post-infection we
expected WNV replication to be very sensitive to the efficiency of translation due to the low
availability of translation competent viral RNA molecules caused by the low rate of synthesis of
viral RNA characteristic of the early life cycle51.
Comparison of the levels of 66 nuclear tRNAs in infected and non-infected A172-KD cells
indicated that WNV infection decreased the expression of 10 tRNAs while 7 were up-regulated
(Fig. 2.5a). The limited effect of WNV on the tRNA pool contrasted with the global up-regulation
of tRNAs triggered by HIV-1 in cells expressing low levels of Slfn1169. Out of these 17 tRNAs, 9
were down-regulated and 1 was up-regulated by WNV infection in A172-KD cells (Fig. 2.5b), and
none of these 10 tRNAs were modified in either in A172-SCR or -BC when infected cells and non51

infected cells were compared. Then, these WNV-induced tRNA changes were considered Slfn11specific (Fig. 2.5b).
Notably, the tRNAs down-regulated by WNV in Slfn11-deficient cells (Fig. 2.5b) were
implicated in decoding 19.2% of the viral codons, while those found up-regulated corresponded
only to 7.7%. Analysis of the impact of tRNA changes on codons that WNV uses
disproportionately more than human cells (rare codons, 12.3 % of the WNV codons) indicated that
the cognate tRNA of 28.5 % of them were decreased by WNV infection in A172-KD cells,
representing 3.5% of all the WNV codons. The codons affected by tRNA reductions were
randomly distributed along the viral genome.
WNV infection did not consistently down- or up-regulate any of the 66 tRNAs analyzed in
both A172-SCR and -BC cells (Fig. 2.5a). Instead, we noticed that tRNAs have a tendency to be
up-regulated in A172-SCR and down-regulated in A172-BC following WNV infection. In A172SCR cells 17 tRNAs increased; however, in A172-BC eight of them did not change and the other
four decreased (Fig. 2.5a). This inconsistency suggests that these changes were independent of
Slfn11. Alternatively; it could reflect a higher Slfn11 tRNA nucleolytic activity in A172-BC than
in A172-SCR cells, as the engineered cells express more Slfn11 than A172-SCR cells (Fig. 2.2a).
Nevertheless, WNV replicated similarly in A172-SCR and -BC cells, indicating that these changes
in tRNA abundance did not impact WNV replication. Furthermore, analysis of the impact of tRNA
down-regulation in A172-BC on the WNV polyprotein indicated that tRNAs in this group that
exhibit statistically significant changes decode only common codons that represent 8.7% of the
WNV genome (Fig. 2.5c).
WNV infection also modulated the expression of tRNAs that reprogram stop codons to
encode specific amino acids (Fig. 2.5a). Genetic code reprogramming allows translation beyond
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stop codons producing fusion proteins91. WNV infection decreased the levels of the tRNASec(TCA)
in A172-KD cells but not in cells expressing Slfn11, indicating that this change was Slfn11specific. This tRNA incorporates selenocysteine in selenoproteins at the UGA stop codon.
Furthermore, WNV infection diminished the expression of tRNASup(CTA) in A172-BC cells that
redefines the stop codon UAG (Amber suppressor); however, this change was not observed in
A172-SCR cells that also express Slfn11.
In conclusion, the changes in the tRNA repertoire inflicted by WNV infection suggests that
the virus will encounter more restrictions to protein translation in Slfn11-deficient cells than in
cells expressing this protein. This seems contradictory with the more robust WNV replication
observed in these cells. However, multiple lines of evidence (discussed later) indicate that a
reduced availability of cognate tRNAs pauses translation at elongation favoring either protein
production and/or optimal protein folding92–100. The later mechanism enhances viral fitness 101.
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Figure 2.5 Effect of WNV infection on the tRNA pool of Slfn11-deficient and control cells.
(a) Heat map of fold changes of the 66 tRNA quantified. Each cell represents the tRNA ratio of
infected/non-infected cells for each of the three cell lines evaluated. tRNAs that increase (red
cells), decrease (green cells) or do not change (black cells) are indicated. The cut-off was set at 1.75 to 1.75-fold change. tRNAs modulated in A172-KD cells by WNV infection. (b) WNVinduced, Slfn11-specific tRNA changes. Fold differences represents the A172-KD infected/noninfected tRNA ratio. (c) WNV-induced tRNA changes in A172-BC cells. Fold differences
represents the A172-KD infected/non-infected tRNA ratio. In (b) and (c) the statistical significance
of the changes in tRNA levels is represented by the calculated p values. The percentage of codons
decoded by each tRNA is indicated. Rare codons are marked with an asterisk.
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2.3.5 Lack of Antiviral Activity of Slfn11 in HEK293T, HeLa, and BHK-21
Cells
Slfn11 has been shown to mediate antiviral activity in cells expressing endogenous Slfn11
such as CEM, HEK29369,81, and A172 cells (Fig. 2.2b). However, the anti-WNV activity of this
protein has not been evaluated in cells that naturally lack the expression of Slfn11 under basal
conditions and/or following type I IFN stimulation (Fig. 2.1d). Among them, we characterized the
WNV-permissive cell lines HEK293T, HeLa, and baby hamster kidney fibroblasts (BHK-21).
These cell lines were engineered to express Slfn11 (HEK293T Slfn11, HeLaSlfn11, and BHK-21Slfn11
cells) (Fig. 2.6a) and then used in viral infection experiments.
HEK293T-derived cells were infected with WNV at MOI 0.1 and viral replication was
determined by plaque assay as described above. WNV replicated robustly in these cells (Fig. 2.6b1) with a kinetic similar to the replication in A172 cells (Fig. 2.1a). However, WNV replication
was indistinguishable between HEK293T cells expressing or not Slfn11 (Fig. 2.6b-1).
To further corroborate the lack of activity of Slfn11 in cells that do not naturally produce
it, we evaluated the susceptibility of HEK293T and HEK293TSlfn11 cells to a single-round infection
HIV-1-derived reporter virus (Hluc). This virus expresses p24 and luciferase proteins from the
viral promoter83. Slfn11 has been reported to affect expression of codon-biased but not unbiased
open reading frames69,81; therefore, we expect that HIV-1 p24, but not luciferase activity, will be
affected by expression of Slfn11 in HEK293T cells.
HEK293T and HEK293TSlfn11 cells were infected with Hluc and luciferase activity and p24
levels were measured in cell lysates and in the cell supernatant of infected cells, respectively, 4
days after infection. As expected, we did not observe any significant effect of Slfn11 on luciferase
expression. Cells expressing Slfn11 exhibited 1,740.4 +/- 121 arbitrary units (AU)/ml compared
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to parental cells that produced 1,188.4+/- 94.2 AU/ml. However, both luciferase-normalized (Fig.
2.6b-2) and non-normalized (data not shown) HIV-1 p24 levels were not affected by Slfn11
expression in HEK293T cells.
In contrast to HEK293T cells, the parental cell line HEK293 expresses endogenous Slfn11
and supports the anti-HIV-1 activity of this protein69. Therefore, we determined the effect of
Slfn11 on WNV replication in HEK293. Control and Slfn11-deficient cells (Fig. 2.6a) were
infected with WNV at a MOI of 0.1 and viral replication was followed by plaque assay as described
above. WNV replication was very robust in HEK293 cells; however, Slfn11 knockdown
significantly enhanced viral replication (DF=7, F=8.11, P<0.0001, Fig. 2.6c). These results
demonstrated the anti-WNV activity of Slfn11 in HEK293 cells.
As an additional control, we evaluated the effect of Slfn11 on HIV-1 in A172-derived cells.
Contrary to HEK293T cells, A172 cells express endogenous Slfn11 (Fig. 2.1d). A172-SCR, -KD,
and -BC cells were infected with Hluc and four days later luciferase activity was measured in cell
lysates and the expression of HIV-1 p24 in the cell supernatant. In these experiments we found
similar levels of luciferase activity among the different cell lines evaluated indicating that Slfn11
levels did not affect the expression of a codon unbiased HIV-driven gene. A172-SCR cells
produced 1,072 +/- 15 AU/ml and A172-KD cells 1.227.5+/- 6.1 AU/ml, whereas A172-BC cells
exhibited 1,289.4 +/- 11.1 AU/ml of luciferase activity. In contrast to HEK293T cells, luciferasenormalized (Fig. 2.6d) and non-normalized (data not shown) HIV-1 p24 expression was 2-fold
higher in A172-KD cells than in -SCR and -BC cells. Thus, these results were in agreement with
previously reported observations in CEM and HEK293 cells 69, indicating that Slfn11 restricts HIV1 in A172 cells. Furthermore, results in figure 2.6d indicate that Slfn11 similarly impaired HIV-1
infection in A172-SCR and -BC cells despite their differences in Slfn11 expression levels (Fig.
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2.2a). These findings are in agreement with the saturating effect that we described above for the
anti-flavivirus activity of Slfn11 (Fig. 2.2), further supporting our hypothesis that Slfn11 is not the
limiting factor of the antiviral pathway.
We hypothesized that the absence of antiviral activity of Slfn11 in HEK293T cells could
be due to mislocalization of the exogenously expressed protein. Thus, we determined the
subcellular distribution of Slfn11 in HEK293TSlfn11 cells by immunofluorescence analysis as
described above. Similar to A172 cells (Fig. 2.4c), Slfn11 was localized entirely in the nucleus of
HEK293TSlfn11 cells and protein aggregates were not observed (Fig. 2.6e). Therefore, these
findings exclude mislocalization or protein aggregation as a cause for the lack of activity of Slfn11
in HEK293T cells.
Next, we explored the effect of Slfn11 on WNV replication in HeLa and BHK-21 cells
following the procedures described above. HeLa and BHK-21 parental and cells engineered to
express high levels of Slfn11 (HeLaSlfn11 and BHK-21Slfn11 cells, Fig. 2.6a) were infected with
WNV at MOI 0.1 and viral replication was followed by plaque assay. Similarly to HEK293T cells,
replication of WNV in HeLa and BHK-21 was very robust and exhibited a kinetic comparable to
the replication in A172 cells (Fig. 2.6f). However, in contrast to A172 cells, we did not find any
differences in viral replication in HeLa or BHK-21 cells expressing or not Slfn11 (HeLa: DF=6,
F=2.42, P=0.0562; BHK-21: DF=7, F=0.65, P=0.711; Fig. 2.6f).
Furthermore, we determined the effects of Slfn11 on single-round HIV-1 infection in HeLa
cells as described earlier. Similarly to the previous experiments we did not observe differences in
the luciferase levels of HeLa cells expressing or not Slfn11. Parental cells expressed 18.73 +/- 2.63
AU/ml while cells engineered to express Slfn11 have 16.97 +/- 1.59 AU/ml. Importantly, HIV-1
p24 levels were also similar in the HeLa cell lines either prior or after luciferase normalization
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(Fig. 2.6g), indicating that Slfn11 did not impair HIV-1 p24 production in HeLa cells. Therefore,
our data indicated that HEK293T, BHK-21, and HeLa cells do not support the antiviral activity of
exogenously expressed Slfn11. These results further support our hypothesis that Slfn11 is not the
only component of this antiviral pathway.
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Figure 2.6 Evaluation of the antiviral activity of Slfn11 in HEK293T, HeLa, and BHK-21 cells.
(a) Slfn11 expression in HEK293T, HEK293, HeLa, and BHK-21 parental and derived cell lines
as detected by immunoblotting analysis.

(b-1) WNV replication in control HEK293T and

HEK293TSlfn11. Cells were infected with WNV (MOI 0.1) and viral replication was determined by
quantification of the viral titer in the cell supernatant at different hours post-infection by plaque
assay. Statistically significant differences were calculated as described above and are indicated
with asterisks. Mean and standard deviation values represent the variability of the viral titers found
in triplicate plaque assays of samples from 3 independent infection experiments. (b-2) HIV-1
infection of control HEK293T and HEK293TSlfn11. Cells were infected with a replication defective
HIV-1 that expresses LTR-driven luciferase and p24. For all HIV-1 infections, mean and standard
deviation values represent the variability of luciferase-normalized HIV-1 p24 levels found in 3
independent infection experiments. Statistical analysis was performed by t-test. (c) HEK293 and
HEK293-KD cells were infected with WNV (MOI 0.1) and viral replication was determined as
described above. (d) HIV-1 infection of A172-derived cells as described above. Statistical analysis
was performed by ANOVA with Tukey HSD post-hoc test. ** Indicates p<0.01. (e) Cellular
distribution of Slfn11 in HEK293TSlfn11. Cells were fixed/permeabilized and stained with an antiSlfn11 antibody by indirect immunofluorescence (red). Nuclei were labeled with Hoechst (blue).
(f) HeLaSlfn11 and BHK-21Slfn11 were infected with WNV (MOI 0.1) and viral replication was
determined as described above. Statistically significant differences were calculated as described
above and are indicated with asterisks.(g) HIV-1 infection of HeLa and HeLaSlfn11 cells. Cells were
infected with a replication defective HIV-1 as described above.
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Chapter 3: Discussion
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3.1

Summary and Significance of Research Performed
Our data showed that Slfn11 deficiency enhances replication of flaviviruses but not

replication of (-)ssRNA viruses belonging to two different families. These findings considerably
expand our knowledge of the antiviral activity of Slfn11, previously limited to retroviruses before
this work was performed. Our data suggest that Slfn11 may counteract other (+)ssRNA viruses,
although this remains to be tested. This broad antiviral effect is associated with viral-induced
decrease of a subset of tRNAs. Our data are also novel as the effect of viral infection on the tRNA
repertoire is still poorly understood. Our findings will promote research in this area; for example
it is intriguing to investigate whether or not (-)ssRNA viruses change the tRNA repertoire,
although our data would suggest that they do not use this strategy. The fact that Slfn11 opposes
WNV-induced tRNA downregulation also shifts the paradigm of the role of Slfn11 in tRNA
biology. Before this research was conducted there was only one report on the role of Slfn11 in
tRNA abundance. This past work indicated that Slfn11 blocks HIV-1-induced tRNA up-regulation.
In contrast, our data indicates that Slfn11 regulates changes in tRNA abundance independently of
their direction. Indirectly, these findings indicate that the mechanism of Slfn11 implicated in tRNA
pool stability is more complex than previously thought and that it requires other functions of this
protein in addition to its tRNA degradation activity. In support of this new concept, we found that
Slfn11 is required for this antiviral activity in cells endogenously expressing this protein but is not
sufficient in cells that naturally lack endogenous Slfn11 expression. These observations, further
support the notion that although the tRNA nucleolytic activity of Slfn11 may be necessary for the
antiviral function, it is not sufficient and other host factors absent in the cells lacking endogenous
Slfn11 are also required.
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3.2

Mechanisms Potentially Implicated in the Antiviral Activity of Slfn11
Possible mechanisms implicated in the Slfn11 antiviral activity, and their potential

relevance or lack thereof, will be discussed below. Finally, a testable working hypothesis will also
be presented for consideration.

3.2.1

Why Does Slfn11 Seem to Selectively Impair Replication of Lentiviruses and

Flaviviruses but not of (-)ssRNA Viruses?
Considering the lack of response of (-)ssRNA viruses VSV and RVFV to Slfn11, we
propose that these types of viruses do not alter the abundance of the tRNA pool. However, we lack
evidence to support this hypothesis because the effect of viral infection on the host tRNA
composition is understudied. Nevertheless, it was demonstrated that influenza virus does not
change the abundance of the tRNA repertoire102, lending support to our hypothesis.
Currently the exact mechanism by which Slfn11 inhibits viral replication is poorly
understood. As previously mentioned, Slfn11 impairs lentivirus infection, including HIV-1 and
equine infectious anemia virus69,71. This protein blocks HIV-induced up-regulation of tRNAs,
impairing viral protein translation, although the mechanism by which it does so remains purely
speculative.
Slfn11 is able to regulate tRNA availability, which can potentially be a rate-limiting step
for successful translation of host and viral proteins. Therefore, at the beginning of this project we
postulated that Slfn11 could also selectively affect the replication of (+)ssRNA viruses. In contrast
to other RNA and DNA viruses, (+)ssRNA viruses require the immediate translation of the
incoming viral genome, making them more susceptible to changes in protein translation efficiency.
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All other viruses avoid this challenge by producing multiple copies of translation competent RNA
molecules by transcription or replication of the viral DNA or RNA genome. Our data support these
predictions; we found that Slfn11 severely affects replication of flaviviruses, including WNV,
DENV, and ZIKV; however, the replication of (-)ssRNA viruses VSV and RVFV, that belong to
evolutionarily distant families, were not affected. Therefore, the antiviral activity of Slfn11 seems
to be specific for (+)ssRNA viruses and lentiviruses 69. Lentiviruses do not face the translational
challenge described above for (+)ssRNA viruses, since this group transcribes the DNA copy of the
viral genome producing multiple copies of mRNA. However, lentiviral protein translation is
particularly sensitive to the availability of rare tRNAs in the host due to their marked biased codon
usage.
Our hypothesis that (+)ssRNA viruses will be more sensitive to innate immune
mechanisms targeting translation efficiency than other viruses found further support in the results
of a high-throughput screening published when this thesis dissertation work was halfway to
completion.
Schoggins et al. examined the effects of individual ISGs on 14 different viruses from 7
different families. From this screening 47 ISGs were identified as having antiviral effects.
Interestingly, this screening also revealed a striking pattern in the differences between (+)ssRNA
and (-)ssRNA viruses in terms of how ISGs mediate inhibition of infection. (+)ssRNA viruses
were significantly more sensitive to ISG inhibition compared to (-)ssRNA. Furthermore, primary
translation was the most common mechanism by which ISGs inhibited viral replication 1,103.
Importantly, Slfn11 was not identified in this screening.
Translational inhibition is a well-established mechanism by which ISGs mount a strong
antiviral defense. Some of the best studied ISGs that use this antiviral mechanism include protein
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kinase R (PKR), which undergoes autophosphorylation upon binding and activation by dsRNA.
In response to viral infections, activated PKR will then phosphorylate the eIF2α translation
initiation factor which results in arrest of translation of both cellular and viral mRNAs 104. 2’,5’oligoadenylate synthetase (OAS) proteins are also activated upon detection of viral dsRNA,
followed by production of 2’,5’-linked oligoadenylates. These molecules will then bind to and
activate the latent endoribonuclease RNase L, which proceeds to cleave both viral RNA and
mRNA, leading to inhibition of protein synthesis and therefore viral replication104. Other examples
of ISGs involved in inhibition of viral protein synthesis include the zinc finger antiviral protein
(ZAP), which binds to viral RNA and targets it for degradation by recruitment of exosomes 105.
Finally, interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) also targets viruses by
repression of viral protein translation. Upon induction by either dsRNA, IRF-3 or type I IFNs,
IFIT1 sequesters capped RNA lacking a 2’-O-methyl group and prevents translation initiation
factors from binding to the viral RNA template8,106.

3.2.2

How Does Slfn11 Impair Viral Infection?
Similarly to other ISGs, Slfn11 also affects protein translation efficiency, in this case by

regulating tRNA availability. In HIV-1-infected cells, Slfn11 globally decreases tRNA levels in
the infected cells. Interestingly, a closely related member of Slfn11, Slfn13, has given us new
insights into the possible mechanism of Slfn11 in downregulation of tRNAs. Recent work has
shown that Slfn13 inhibits HIV-1 infection in a nucleolytic activity-dependent manner73.
Specifically, Slfn13 cleaves 11 nucleotides from the 3’ end of the acceptor stem of tRNAs, thereby
inhibiting protein synthesis. It is important to note that the catalytic triad and five out of the six
residues implicated in tRNA binding in Slfn13 are conserved in Slfn11, and these two proteins

73

share an overall homology of 83%. Therefore, Slfn11 likely opposes HIV-1-induced tRNA
increase by tRNA degradation.
The enzymatic nucleolytic activity is required for Slfn13 to restrict HIV-1 infection. The
antiviral activity of Slfn13 appears to be specific since this protein did not affect replication of
herpes simplex or Zika viruses (ZIKV)73. Slfn13 seems to be unable to discriminate over tRNA
types, but rather targets tRNA secondary structures. In addition, Slfn13 degrades HIV-1 mRNA
but not mRNA transcribed from plasmids transfected into Slfn13-expressing cells. The effect of
Slfn11 on HIV-1 mRNA has not been directly evaluated, but due to the structural homology of
Slfn11 and 13 and their role in tRNA degradation, it is tempting to speculate that secondary RNA
structures present in HIV-1 and flaviviruses could be targeted by Slfn11.
Similarly, Slfn14 was also recently characterized as a strong endoribonuclease that binds
to ribosomes and ribosomal subunits and preferentially cleaves ribosomal as well as ribosomeassociated RNA107. Although not studied in the context of viral infections, this work does suggest
that Slfn14 could also be induced upon IFN stimulation and upon activation, target cellular RNA
as well as viral RNA in a manner similar to the well characterized, IFN stimulated ribonuclease
RNase L104,108. It is possible that upon infection, activation of ribonucleases such as Slfn13, Slfn14
and possibly, Slfn11, could induce global protein shutdown and thereby promote cell autophagy
and apoptosis. However, we do not favor this possibility since Slfn11 did not affect replication of
the (-)ssRNA viruses VSV and RVFV and Slfn13 failed to impair replication of ZIKV. It is also
important to note that in all three Slfn proteins mentioned above, the N-terminal domain harbors
the catalytically active site responsible for RNA degradation described in Slfn13. Furthermore,
bioinformatics analysis indicates that the Slfn13 catalytically-active residues that mediate the
ribonuclease activity are conserved in many members of the Slfn family in different species,
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ranging from invertebrate to human. The characterization of the antiviral activity of these Slfn
proteins deserves attention.
Our findings also revealed important differences between Slfn11 and Slfn13 in their
specificity. Slfn13 failed to affect ZIKV replication73 whereas we found Slfn11 effective against
this virus. These functional differences highlight the lack of redundancy in the antiviral specificity
of different members of the Slfn family. Importantly, human placenta and testes lack expression
of Slfn11, otherwise, a ubiquitously expressed protein81. We therefore suggest the possibility that
the lack of expression of Slfn11 in these tissues could significantly influence mother to fetus and
sex-related transmission of ZIKV109,110.

3.3

Slfn11 Could Affect Viral Replication Through a Translation-

Independent Mechanism
3.3.1

Innate Immune Signaling
As previously mentioned, Slfn14 has also been recently shown to be an effective antiviral

factor against influenza A and varicella zoster virus72. However, the antiviral mechanism is
independent of regulation of protein translation efficiency. Importantly, this work showed that
Slfn14 induction is mediated by the TLR-3 and type I IFN pathways and that once induced, it
enhances RIG-I-mediated IFN-β signaling. Although not experimentally, the authors also address
the peculiar similarity of the putative RNA helicase motif present in the C-terminal sections of
group III Slfn proteins (Slfn5, Slfn11, Slfn12, Slfn13, and Slfn14) with that of the DNA/RNA
nucleic acid sensors retinoic acid inducible gene-I (RIG-I) and melanoma differentiation
associated gene 5 (MDA5). Therefore, it is possible that Slfn14 binds to viral RNA and/or DNA
and upon activation participates in and enhances IFN-mediated restriction of viral replication.
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Altogether, accumulating data suggests that Slfn proteins might not only play a role in the innate
immune response as direct antiviral effectors, but could also be important regulators of innate
immune signaling.

3.3.2

Translation-Independent Functions of tRNAs
Besides their canonical function in protein synthesis, tRNAs also participate in diverse

cellular processes through the activity of tRNA-derived fragments (tRFs). These small non-coding
RNA molecules influence cellular metabolism, cell death, and gene expression through different
mechanisms, although the overall function of tRFs remains unknown111. Previous work has shown
that under cellular stress, the ribonuclease protein Angiogenin (ANG) cleaves mature cellular
tRNAs at the anticodon loop to produce 5′- and 3′-tRNA fragments112. These fragments are then
able to promote translational repression by displacing eIF4G/A from capped and uncapped mRNA
and eIF4E/G/A (eIF4F) from the m7G cap, therefore impeding translation initiation112.
Furthermore, it was shown that Respiratory Syncytial Virus (RSV) utilizes ANG to produce these
tRFs, presumably to suppress antiviral responses113. It has been also shown that ANG inhibitors
increase HIV-1 replication114. We verified this observation; however, we did not observe any effect
of this inhibitor on WNV infection (data not reported in this work).
Modulation of tRF production could also be implicated in the antiviral mechanism of
Slfn11. The work presented here indicates that similarly to HIV-1, WNV modifies the tRNA pool
and Slfn11 opposes these changes. It is possible that Slfn11, by stabilizing the tRNA repertoire,
also prevents changes in the host tRFs that could antagonize viral replication. However, evidence
supporting this mechanism is missing.
Interestingly, our data indicate that WNV infection of Slfn11-deficient cells causes a
drastic decrease of tRNAHis. Despite the fact that this tRNA is the least abundant, it contributes to
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27% of the tRF pool115. This disproportion suggests a functional relevance of this tRF. Potentially,
WNV infection could diminish production of this tRF by decreasing the levels of tRNAHis or
increase its generation causing the observed reduction in tRNAHis. In any case, it would also be
interesting to evaluate this potential mechanism.
tRNA molecules are among the most stable RNAs in the cell. Unlike mRNA, which can
have a half-life ranging from minutes to hours, tRNA half-lives tend to be in the order of days.
This superior stability is mainly a consequence of the complex folded structure, as well as the
various modifications of tRNAs111,116. Evidence shows that loss of function of the RNA
methyltransferase NSun2, responsible for modifying cytosine-5 in tRNAs, leads to cleavage of
tRNAs by ANG, and subsequent production of 5’ and 3’ tRFs. In the absence of NSun2,
accumulation of these tRFs interferes with the cellular translation machinery and activates stress
response pathways that lead to the reduction of cell size as well as increase in apoptosis in cortical,
hippocampal and striatal neurons117. In line with the well-defined molecular mechanisms of
NSun2, it is not surprising that genetic mutations or deletion of Nsun2 in the brain is linked with
neuro-developmental disorders such as microcephaly118,119, possibly as a consequence of stressinduced tRNA cleavage by ANG. As previously mentioned, our data indicates that flaviviruses
decrease the tRNA repertoire of the host to enhance viral replication. Although not supported
experimentally, it is intriguing to hypothesize that severe neurological consequences, such as
microcephaly, could be the result of regulation or disruption of cellular processes (e.g. NSun2ANG-mediated disruption of protein synthesis) by neurotropic viruses such as ZIKV. However,
the levels of NSun2 do not change in the course of ZIKV replication in A172 cells (Data not
included here).
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3.4

How do Viruses Regulate tRNA Abundance?
Ours and previously published data69,120 suggest that lentiviruses and flaviviruses have

evolved different strategies to enhance viral replication by modulating the tRNA pool. Lentiviruses
increase tRNA levels in the cell resulting in a higher availability of tRNAs required for the
translation of their codon-biased genome. Therefore, these changes in the tRNA pool lead to
enhanced viral protein translation. In contrast, flaviviruses, which lack codon-biased genomes,
diminish the abundance of a subset of tRNAs, predictably reducing the efficiency of viral protein
production, and nonetheless, increasing virus replication.
The mechanisms implicated in viral-induced modification of the tRNA repertoire are
currently unknown. HIV-1-induced tRNA increase could be due to enhanced transcription or
decreased degradation of these molecules. However, no data supporting any of these two avenues
is available. The long half-life of tRNA indicates that WNV-induced tRNA downregulation should
be a consequence of increased degradation rather than decreased synthesis. Nevertheless, a
potential mechanism in WNV-induced downregulation of tRNAs is through the regulation of
Maf1, a negative modulator of RNA polymerase III (Pol III). Maf1 is phosphorylated via protein
kinase A and TOR-dependent Sch9 kinase and retained in the cytoplasm of the cells. The
serine/threonine protein phosphatase 2 (PP2A) removes this phosphorylation signal inducing
nuclear migration and association with Pol III. An inhibitor of PP2A, I2PP2A, prevents Maf1
dephosphorylation and therefore inhibition of tRNA transcription by Pol III111. Importantly, WNV
capsid protein binds to I2PP2A, blocking the inhibitory effect on PP2A121. Potentially, WNV capsid
could inhibit tRNA transcription through this non-structural function. If this pathway is implicated
in the WNV-induced changes in the tRNA repertoire, it is still intriguing why only a subset of
tRNAs are decreased in Slfn11-deficient cells upon WNV infection.
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The Maf1/capsid pathway is predicted to affect tRNAs globally and not only a subset of them. A
possibility could be that at the early time post-infection that we examined, only the less abundant
tRNAs in A172 cells are down-regulated (e.g. tRNAHis). However, tRNAAla, which is the most
abundant in cells111,122, was also down-regulated by WNV infection. Similarly, there was no
correspondence between the basal levels of tRNAs and their sensitivity to WNV infection in
Slfn11-deficient cells, indicating that the sensitivity to WNV was not due the basal levels of tRNAs
in human cells.
The above considerations prompt us to postulate that WNV infection triggers degradation
of tRNAs in cells lacking Slfn11. In contrast to the vastly investigated processes involved in the
degradation of mRNA, much less attention has been directed at the degradation of stable tRNA.
Two major tRNA degradation pathways have been described as being so far. The nuclear
surveillance pathway is known to affect only pretRNAiMet. This pathway monitors pre-tRNA
quality during the initial stages of tRNA biogenesis. Previous work has shown that tRNA iMet
lacking a methylated adenine at position 58 (m1A58) will activate the Trf4 (topoisomerase 1-related
4)/Air2 (Arginine methyltransferase-interacting RING finger protein 2)/Mtr4p (mRNA transport
regulator 4 protein) Polyadenylation (TRAMP) complex which polyadenylates the pre-tRNA,
leading to 3’-end degradation by the nuclear exosome111,116. The second pathway described is
called rapid tRNA decay (RTD), which unlike the nuclear surveillance pathway, primarily targets
mature tRNAs and involves cytoplasmic and nuclear exonucleases. During this process, tRNAs
lacking a specific methylated guanosine (m7G46) or methylated cytidine (m5C49) modification, as
well as tRNAs displaying instability at the acceptor stem, are degraded by the Xrn1 or Rat1
exonucleases111,116. Strong evidence suggests that the RTD pathway seems to be general since
various tRNAs lacking different combinations of modifications are also targeted by this pathway.
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Alternatively, the cellular stress caused by WNV infection could produce changes in the
tRNA repertoire. It has been demonstrated in yeast that different chemical stressors trigger specific
changes in tRNA repertoire characterized by either increase or decrease of certain tRNAs123.
Nevertheless, the degradation pathway implicated in this phenomenon is unknown.
The mechanism used by Slfn11 to prevent WNV-induced downregulation in the tRNA repertoire
is also unknown. Theoretically, this could be through increasing tRNA synthesis or preventing
tRNA degradation. Previous work has shown that activation of NF-kB by bacterial
lipopolysaccharides (LPS) leads to upregulation of Pol III and subsequent increase in tRNA gene
transcription124. Although no link between Slfn11 and NF-kB has been reported, Slfn2 has
recently been shown to regulate NF-kB expression by interacting with PPP6R1, a subunit of
protein phosphatase-6 (PP6), a member of the PPP family of Ser/Thr phosphatases, proteins found
to be integral in the NF-kB signaling pathway125. Although no experimental evidence is available,
a precedent for Slfn family members being directly involved in this signaling pathway certainly
makes us consider the intriguing possibility that Slfn11 could potentially counteract WNV-induced
downregulation of tRNAs through a Slfn11-NF-kB-mediated upregulation of Pol III-transcribed
tRNA genes125. We believe that the effect of NF-kB-inhibitors on the anti-WNV activity of Slfn11
should also be evaluated.
Combined analysis of ours and previous findings 69 demonstrate that Slfn11 impairs HIV1 and WNV through a similarly mechanism. In both cases the N-terminal region of Slfn11 is
necessary and sufficient for antiviral activity and this protein blocks virus-induced changes in the
tRNA repertoire of the infected cells. However, HIV-1 globally increased tRNAs in the absence
of Slfn11; in contrast WNV infection only decreased a subset of tRNAs in Slfn11-deficient cells.
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These findings suggest that Slfn11 opposes virus-induced changes in the tRNA pool independently
of their direction.

3.5

Effect of Virus-Induced Changes in tRNA Levels on Viral Protein

Synthesis
HIV-1 induces global increase of the size of the tRNA pool. This is advantageous for
lentiviral protein translation because of the strong codon bias observed in these viruses as
compared to their host.
Interestingly, flaviviruses do not exhibit codon bias and do not increase tRNA levels; in
contrast, these viruses seem to decrease the levels of a subset of host tRNAs. This change causes
pausing during translational elongation. Multiple lines of evidence indicate that translational
elongation pausing at codons recognized by low abundance tRNAs might promote efficiency of
protein production and/or optimal protein folding92,94–100. A common pattern of 30-50 rare codons
clustering immediately downstream of the start codon is present in highly expressed prokaryotic
and eukaryotic genes. It is thought that this “ramp” sequence increases protein synthesis efficiency
by reducing ribosome stalling during translational elongation97. However, it is unlikely that the
WNV-induced tRNA decrease will enhance viral replication by this mechanism as the codons
affected do not cluster in the viral genome.
Furthermore, it has been proposed that rare codons decrease the speed of translational
elongation potentially facilitating protein folding126. In the RNA replicase and 3C protease of footand-mouth disease virus94,99 and in a Neurospora crassa circadian clock protein, a link between
location of rare codons and protein secondary structures was described 100. This link was also
predicted by bioinformatics analysis of E. coli, S. cerevisiae, Caenorhabditis elegans, and
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Drosophila melanogaster genomes100. The location of these codons in the transition boundaries of
protein secondary structures suggests that the modulation of the speed of the translation elongation
is necessary for proper protein folding126. Furthermore, replacement of native rare codons by
synonymous common codons in the capsid of poliovirus127 and hepatitis A virus92 caused a
decrease in viral fitness, suggesting that optimal protein folding due to low abundance of tRNA
results in increased viral fitness. Therefore, we postulate that WNV-induced reduction in tRNA
abundance in Slfn11-deficient cells leads to optimal viral protein folding and enhanced viral
fitness.

3.6

The Antiviral Activity of Slfn11 Requires Other Host Cofactors
Intriguingly, we observed that exogenously expressed Slfn11 is not functional against HIV-

1 or WNV infection in HEK293T, HeLa, and BHK1 cells that naturally lack endogenous
production of this protein. These observations suggest the existence of a cofactor(s) required for
the Slfn11 antiviral mechanism. Likely, the missing cofactor(s) is not necessary for the Slfn13like tRNA nucleolytic activity73 that we predict is present in Slfn11 based on the conservation of
key amino acids. Purified recombinant Slfn13 cleaves purified tRNAs in vitro, indicating that other
proteins are not required for this activity. Furthermore, co-transfection of plasmids expressing
Slfn11 and codon-biased cDNAs in HEK293T cells impaired the expression of the reporter
proteins suggesting conservation of the putative Slfn11 tRNA nucleolytic activity in these cells81.
Thus, together these observations suggest that the tRNA nucleolytic activity of Slfn11, although
required, is not sufficient for its antiviral activity.
Furthermore, we observed a lack of correlation between the levels of Slfn11 and the
antiviral effect of this protein. Slfn11 affected HIV-1 and flavivirus infection in A172-SCR and BC cells to a similar extension despite the fact that these cells express markedly different levels of
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Slfn11. These observations indicate that above certain amounts of Slfn11, the antiviral activity of
this protein reaches saturation. This phenomenon will be unexpected if the antiviral activity of
Slfn11 does not require other cofactor(s). Therefore, these data also support our hypothesis that
Slfn11 is not the limiting factor of the antiviral pathway.

3.7

Physiological Role of Slfn11
The proposed role of Slfn11 in maintaining the stability of the tRNA pool could also

explain the direct correlation between the sensitivity of cells to genotoxic drugs and their Slfn11
levels. It has been found that cancer cells expressing higher levels of Slfn11 are more sensitive to
DNA-damaging agents70,128,129. Therefore, it is possible that higher levels of Slfn11 could reduce
the abundance of specific tRNAs in the cell affecting protein synthesis, as recently reported81. This
effect will down-regulate the levels of DNA repair proteins encoded by codon-biased open reading
frames130, increasing the susceptibility of cancer cells to genotoxic agents.

3.8

Working Hypothesis
Although we ignore how Slfn11 affects flavivirus replication, we propose that these viruses

trigger degradation of a subset of tRNAs, causing pausing of virus translation at elongation. This
will lead to enhanced protein folding and increased viral fitness. In contrast, lentiviruses will
increase tRNA abundance globally to overcome the tRNA functional deficiency that results from
its codon bias, facilitating viral protein translation. Slfn11, in concert with other cellular protein(s),
prevents these changes in tRNA abundance, impairing viral replication. It is possible that Slfn11
tRNA nucleolytic activity could be negatively regulated upon virus-induced tRNA decrease. This
non-nucleolytic form of Slfn11 could still bind tRNAs, protecting them from degradation. In the
case of HIV-1, virus-induced tRNA upregulation will be counteracted by the tRNA nucleolytic
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activity of Slfn11. The protein(s) missing in the cells that do not support Slfn11 activity could
sense the changes in tRNA levels and transduce this signal to Slfn11.
In summary, our data has revealed that Slfn11 opposes virus-induced changes in the tRNA
repertoire, thus affecting evolutionarily unrelated viruses that manipulate the host tRNA repertoire
to facilitate viral replication. Although the exact mechanism by which Slfn11 inhibits protein
synthesis requires a considerable amount of further analysis, we believe that our findings establish
Slfn11 as an important cellular protein involved in control of viral replication. Furthermore, a
better understanding of the role of Slfn11 during viral replication will also improve our knowledge
of flavivirus pathogenesis and possibly provide the foundation for the exploration of new
therapeutic avenues with which to treat these diseases.

3.8.1

Validation of Working Hypothesis

1. We propose that flaviviruses trigger degradation of a subset of tRNAs, which causes
pausing of virus translation at elongation. We need to demonstrate that flavivirus and HIV1 viral RNA is not degraded by Slfn11. This can be done by quantifying by RT-PCR the
levels of the viral RNA in infected cells expressing or not Slfn11. Furthermore, codon
optimization of WNV to remove the codons read by the tRNAs that are selectively
downregulated by the viral infection is expected to remove the increased viral replication
in Slfn11-deficient cells.
2. We propose that pausing in translation will lead to enhanced protein folding and increased
WNV fitness. To validate this hypothesis, we need to determine the viral titer normalized
to the amount of viral particles. Virion quantification can be performed by measuring a
virus structural protein by ELISA.
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3. It is possible that Slfn11 tRNA nucleolytic activity could be negatively regulated upon
virus-induced tRNA decrease. This non-nucleolytic form of Slfn11 could still bind tRNAs,
protecting them from degradation. In the case of HIV-1, virus-induced tRNA upregulation
will be counteracted by the tRNA nucleolytic activity of Slfn11. Therefore, we expect that
catalytically-inactive Slfn11 mutants will still prevent WNV replication but will fail to
impair HIV-1 infection.
4. The protein(s) missing in the cells that do not support Slfn11 activity could sense the
changes in tRNA levels and transduce this signal to Slfn11. We will characterize Slfn11
interacting proteins implicated in the antiviral activity. We expect that the missing
protein(s) is expressed in cells that support Slfn11 activity but not in the non-supportive
cells. Therefore, we will determine the identity of this protein(s) by combining gene
expression analysis of supportive and non-supportive cells with results of experiments
looking at Slfn11 interactors present in supportive but absent in non-supportive cells. This
protein(s) will be identified using different techniques such as BioID, immunoprecipitation
followed by proteomic analysis, and yeast-two hybrid screening.
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